Télécharger la liste des 67 posters

Transcription

Participation IUCT Oncopole - CRCT
67 posters
dont 3 communications orales et 9 posters 1er auteur
Communications orales
1142 Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By
Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly
Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du
MyéLome (IFM) Krd Phase II Study
Myeloma: Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and
Maintenance Therapy
1*
2*
3*
4*
Murielle Roussel, MD , Valerie Lauwers-Cances, MD , Nelly Robillard, PhD , Karim Belhadj, MD , Thierry
5
6
7*
8*
Facon, MD, PhD , Laurent Garderet, MD , Martine Escoffre, MD , Brigitte Pegourie, MD , Lotfi Benboubker,
9*
10*
11*
12*
13
14*
MD, PhD , Denis Caillot , Cecile Fohrer, MD , Philippe Moreau , Xavier Leleu , Hervé Avet-Loiseau and
15
Michel Attal
1
Institut Universitaire du Cancer, toulouse, France
2
USMR, service d'Epidemiologie, CHU Toulouse, TOULOUSE, France
3
Hematology Laboratory, Nantes University Hospital, Nantes, France
4
CHU Henri Mondor, Creteil, France
5
Maladies du Sang, Lille University Hospital, Lille, France
6
Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
7
CHU Rennes, Rennes, France
8
Hôpital A.Michallon, CHU Grenoble, Grenoble, France
9
Hôpital Bretonneau Service Hématologie et Thérapies Cellulaires, Centre Régional de Cancérologie Henry
Kaplan CHRU de Tours, Tours, France
10
Hématologie Clinique, Dijon University Hospital, Dijon, France
11
HEMATOLOGY, CHU, Strasbourg, FRA
12
Department of Hematology, Nantes University Hospital, Nantes, France
13
ONCOLOGIE HEMATOLOGIQUE ET THERAPIE CELLULAIRE, CHU DE POITIERS, POITIERS, France
14
IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France
15
Institut Universitaire du Cancer-Oncopole, Toulouse, France
762 The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute
Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study
Acute Lymphoblastic Leukemia: Clinical Studies
Type: Oral
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: New Approaches to Treatment Stratification and
MRD Utilization
1*
2*
3
4
Françoise Huguet, MD , Thibaut Leguay , Xavier Thomas, MD, PhD , Nicolas Boissel, MD, PhD , Martine
5*
6*
7*
8
Escoffre-Barbe, MD , Patrice Chevallier, MD, PhD , Mathilde Hunault, MD, PhD , Norbert Vey, MD , Caroline
9*
10*
11
12,13
Bonmati, MD , Stéphane Leprêtre, MD , Jean-Pierre Marolleau, MD, PhD , Thomas Pabst, MD, PhD ,
14*
15*
16
17*
Philippe Rousselot, MD, PhD , Agnès Buzyn, MD, PhD , Jean-Yves Cahn, MD , Véronique Lhéritier , Marie C
18*
19*
20*
Béné, PharmD, PhD , Vahid Asnafi, MD, PhD , Eric Delabesse, PharmD, PhD , Elizabeth Macintyre, MD,
21
13,22
23
24*
PhD , Yves Chalandon, MD , Norbert Ifrah and Hervé Dombret, MD
1
Department of Hematology, Institut Universitaire de Cancérologie de Toulouse, Toulouse, France
2
Hematology, Bordeaux University Hospital, Pessac, France
3
Departement of Hematology, Centre Hospitalier Lyon Sud, HCL, Pierre Bénite, France
4
Hématologie Adulte, Saint-Louis Hospital, APHP, Paris, France
5
Departement of Hematology, CHU Rennes, Rennes, France
6
Department of Hematology, CHU, Nantes, France
7
Hematology, Medical University Hospital, Angers, France
8
Department of Hematology, Institut Paoli Calmettes, Marseille, France
9
Department of Hematology, Hôpitaux de Brabois, Vandoeuvre Lès Nancy, France
10
Department of Hematology, CLCC H Becquerel, Rouen, France
Department of Hematology, CHU, Amiens, France
12
Department of Hematology, Bern University Hospital, Bern, Switzerland
13
Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
14
Department of Hematology, Hôpital André Mignot, Versailles, France
15
Departement of Hematology, Hôpital Saint Antoine, AP-HP, Paris, France
16
Hematology, CHU Grenoble Alpes, Grenoble, France
17
GRAALL Coordination, Lyon-Sud University Hospital, Pierre-Bénite, France
18
Departement of Immunology, CHU, Nantes, France
19
Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, APHP, Paris, France
20
Laboratory of Hematology, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
21
Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, AP-HP, Paris, France
22
Division of Hematology, Geneva University Hospitals, Geneva, Switzerland
23
Departement of Hematologie, CHU, Angers, France
24
Departement of Hematology, Hôpital Saint-Louis, AP-HP, Paris, France
11
246 Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM)
Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib
Plus Dexamethasone
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and
Biomarkers
1*
2*
3*
4
5
Hervé Avet-Loiseau , Tineke Casneuf , Christopher Chiu, PhD , Jacob P. Laubach, MD , Je-Jung Lee , Philippe
6*
7
8*
9*
10*
11*
Moreau , Torben Plesner, Professor , Hareth Nahi , Nushmia Z Khokhar , Ming Qi , Jordan Schecter ,
12*
9*
11*
13
14
Victoria Carlton, Ph.D. , Xiang Qin , Kevin Liu , Kaida Wu, MD, PhD , Sen H. Zhuang, M.D., Ph.D. ,
9*
9*
15
Tahamtan Ahmadi, MD , A. Kate Sasser, PhD and Jesús F. San-Miguel
1
Centre Hospitalier Universitaire Rangueil, Unité de Genomique du Myelome, Toulouse, France
2
Oncology Heme Translational Research Group, Janssen Research & Development, Beerse, Belgium
3
Oncology Heme Translational Research Group, Janssen Research & Development, LLC, Spring House, PA
4
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea,
The Republic of
6
7
Department of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark
8
Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
9
Janssen Research & Development, LLC, Spring House, PA
10
Janssen Research & Development, Spring House, PA
11
Janssen Research & Development, LLC, Raritan, NJ
12
Adaptive Biotechnologies Corp, South San Francisco, CA
13
Janssen Oncology, Springhouse, PA
14
Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ
15
Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain
Posters
674 Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell
Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple
Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)
Clinical Autologous Transplantation: Results
Type: Oral
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
1*
2*
3*
4*
5*
Philippe Moreau, MD , Cyrille Hulin, MD , Denis Caillot , Gerald Marit, MD , Aurore Perrot, MD , Laurent
6
7
8*
9*
10*
Garderet, MD , Thierry Facon , Lotfi Benboubker, MD, PhD , Lionel Karlin, MD , Mourad Tiab , Bertrand
11*
12
13
14*
15*
Arnulf, MD , Jean-Paul Fermand , Xavier Leleu , Cyrille Touzeau, MD , Murielle Roussel, MD , Lucie
16*
17*
18*
15*
Planche , Stephane Minvielle , Marie-Christine Bene, PharmD , Hervé Avet-Loiseau , Thomas Dejoie,
19*
20
PharmD and Michel Attal
1
hematology department, university hospital, nantes, France
2
hematology department, university hospital, bordeaux, France
3
4
hematology department, university hospital, Bordeaux, France
5
hematology department, university hospital, Vandoeuvre Les Nancy, France
6
Hematology Department, CHU St Antoine, Paris, France
7
Hematology, CHRU Lille Hôpital Claude Huriez, Lille, Lille, France
8
CHU Tours Hopital Bretonneau, Tours, France
9
hematology department, Hospices Civils de Lyon, PIERRE BENITE CEDEX, FRA
10
University Hospital, La Roche Sur Yon, France
11
hematology department, Hôpital Saint Louis, Paris, France
12
Hopital Saint-Louis, Paris, France
13
CHU DE POITIERS, POITIERS, France
14
Department of hematology, Nantes university Hospital and UMR892 INSERM, Nantes, France
15
hematology department, university hospital, toulouse, France
16
university hospital, nantes, France
17
Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France
18
Hopital Hotel Dieu, Laboratoire d'Hematologie, Nantes, France
19
Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, France
20
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
1636 Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute
Myeloid Leukemia
Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I
1,2
1*
3*
4,5*
Christian Récher, MD-Ph.D. , Sarah Bertoli, M.D; Ph.D , Muriel Picard, M.D , Emilie Bérard, M.D; Ph.D ,
2*
1*
6*
7*
8*
Clément Larrue, PhD , Suzanne Tavitian, M.D , Francois Vergez, DVM, Ph.D , Edwige Yon , Jean Ruiz, M.D ,
9,10*
6*
11*
12
Eric Delabesse, PharmD, PhD , Isabelle Luquet, M.D , Laetitia Linares, PhD , Martin Carroll, MD , Audrey
13*
13*
2*
Sarry , Françoise Huguet, M.D and Jean-Emmanuel Sarry, PhD
1
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse,
France
2
Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
3
Service de Réanimation, CHU de Toulouse, Toulouse, France
4
Service d'Epidémiologie,, CHU de Toulouse, Toulouse, France
5
UMR 1027, INSERM-Université de Toulouse III, Toulouse, France
6
Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse,
France
7
Service d'Epidémiologie, CHU de Toulouse, Toulouse, France
Service de Réanimation médicale, CHU de Toulouse, Toulouse, France
9
Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France
10
11
Institut de Recherche en Cancérologie de Montpellier, INSERM, U1194, Montpellier, France
12
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
13
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse,
France
8
3736 Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly
Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry
Disorders of Platelet Number or Function
Session: 311. Disorders of Platelet Number or Function: Poster III
1*
2*
1*
3*
4*
Anaïs Essilini , Thibault Comont , Johanne Germain, PhD , Natacha Brun, MD , Claire Dingremont, MD ,
5*
6*
7*
8*
Brice Castel, MD , Philippe Montané de la Roque, MD , Serge Madaule, MD , Laurent Sailler, MD, PhD ,
9*
10*
11*
12*
Laurent Prudhomme, MD , Sophie Arista, MD , Laurent Balardy, MD , Francis Gaches, MD , Benjamin
13*
14,15*
16*
17*
Hebraud , Cecile Borel, MD
, Stéphane Sire, MD , Miguel Carreiro, MD , Guillaume Martin-Blondel, MD,
11*
11*
18*
19*
PhD , Laurent Alric, MD, PhD , Patrick Giraud, MD , Maryse Lapeyre-Mestre, MD, PhD , Odile Beyne20*
21*
22*
Rauzy, MD, PhD , Daniel Adoue, MD, PhD and Guillaume Moulis, MD, PhD
1
UMR 1027 INSERM-University of Toulouse, Toulouse, France
2
Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
3
Rodez Hospital, Rodez, France
4
Tarbes Hospital, Tarbes, France
5
Lourdes Hospital, Lourdes, France
6
Pamiers Hospital, Pamiers, France
7
Albi Hospital, Albi, France
8
Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-University of Toulouse,
Toulouse, France
9
Castres hospital, Castres, France
10
Auch hospital, Auch, France
11
Toulouse University Hospital, Toulouse, France
12
Ducuing hospital, Toulouse, France
13
Hématologie, CHU Toulouse, Toulouse, France
14
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse - CHU de Toulouse, Toulouse, France
15
IUCT-Oncopole, Toulouse, France
16
Cahors Hospital, Cahors, France
17
Montauban Hospital, Montauban, France
18
Pont de Chaume hospital, Montauban, France
19
Service de Pharmacologie Médicale et Clinique, INSERM U 1027, Toulouse, France
20
Service de medecine Interne, CHU Purpan, Toulouse, France
21
Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse,
Toulouse, France
22
Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France
Introduction.
3996 Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive
Chemotherapy Between 2000 and 2014
Acute Myeloid Leukemia: Clinical Studies
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
1*
2,3*
1*
4*
Sarah Bertoli, M.D; Ph.D , Emilie Bérard, M.D; Ph.D , Suzanne Tavitian, M.D , Anne Huynh, MD , Cecile
5*
1*
6*
7*
4*
Borel, MD , Sarah Guenounou , Isabelle Luquet, M.D , Eric Delabesse, PharmD, PhD , Audrey Sarry , Guy
1
8
4*
1,9
Laurent, M.D; Ph.D , Michel Attal , Françoise Huguet, M.D and Christian Récher, MD-Ph.D.
1
France
2
3
France
5
6
France
7
8
9
4
1367 Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a
Prospective Multicenter Cohort Study of 218 Patients
Session: 311. Disorders of Platelet Number or Function: Poster I
1*
2*
3*
3*
Guillaume Moulis, MD, PhD , Thibault Comont , Johanne Germain, PhD , Anaïs Essilini , Natacha Brun,
4*
5*
6*
7*
8*
MD , Claire Dingremont, MD , Brice Castel, MD , Philippe Montané de la Roque, MD , Serge Madaule, MD ,
9*
10*
11*
12*
Laurent Sailler, MD, PhD , Laurent Prudhomme, MD , Sophie Arista, MD , Laurent Balardy, MD , Francis
13*
14*
15*
16*
17*
Gaches, MD , Benjamin Hebraud , Cecile Borel, MD , Stéphane Sire, MD , Miguel Carreiro, MD ,
12*
12*
18*
Guillaume Martin-Blondel, MD, PhD , Laurent Alric, MD, PhD , Patrick Giraud, MD , Maryse Lapeyre19*
20*
21*
Mestre, MD, PhD , Odile Beyne-Rauzy, MD, PhD and Daniel Adoue, MD, PhD
1
2
Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
3
4
Rodez hospital, Rodez, France
5
Tarbes Hospital, Tarbes, France
6
Lourdes Hospital, Lourdes, France
7
Pamiers Hospital, Pamiers, France
8
Albi Hospital, Albi, France
9
Toulouse, France
10
Castres hospital, Castres, France
11
Auch hospital, Auch, France
12
Toulouse University Hospital, Toulouse, France
13
Ducuing hospital, Toulouse, France
14
Hématologie, CHU Toulouse, Toulouse, France
15
16
Cahors Hospital, Cahors, France
17
Montauban Hospital, Montauban, France
18
Pont de Chaume hospital, Montauban, France
19
20
21
Toulouse, France
3991 Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute
Myeloid Leukemia?
1*
2*
1*
3*
Sarah Bertoli, M.D; Ph.D , Noemie Gadaud , Suzanne Tavitian, M.D , Audrey Sarry , Emilie Bérard, M.D;
4,5*
1*
1,6
Ph.D , Françoise Huguet, MD and Christian Recher, MD, PhD
1
France
2
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
3
France
4
5
6
4764 Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French
National Health Insurance Database
Outcomes Research—Non-Malignant Conditions
Session: 903. Outcomes Research—Non-Malignant Conditions: Poster III
1*
2*
3*
4*
Salim Mezaache , Hélène Derumeaux, MD, PhD , Pierre Ferraro, MD , Pascal Capdebon, MD , Jean5*
6*
7*
8*
Christophe Steinbach, MD , Xavier Aballe, MD , Deborah Palas, MD , Nabil Saichi, MD , Franck Burgan,
9*
10*
11*
12*
MD , Karine Desboeuf, MD , Maryse Lapeyre-Mestre, MD, PhD , Laurent Sailler, MD, PhD and Guillaume
13,14*
Moulis, MD, PhD
1
2
Department of Medical Information, Toulouse University Hospital, Toulouse, France
3
Department of Medical Information, Auch Hospital, Auch, France
4
Department of Medical Information, Tarbes Hospital, Tarbes, France
5
Department of Medical Information, Castres Hospital, Castres, France
6
Department of Medical Information, Montauban Hospital, Montauban, France
7
Department of Medical Information, Albi Hospital, Albi, France
8
Department of Medical Information, Foix-Pamiers Hospital, Pamiers, France
9
Department of Medical Information, Pont-de-Chaume Hospital, Montauban, France
10
Department of Medical Information, Lavaur Hospital, Lavaur, France
11
12
Toulouse, France
13
14
CIC 1436, Toulouse University Hospital, Toulouse, France
3987 Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia
1*
2*
3*
4*
3*
Thibault Comont , Suzanne Tavitian, M.D , Laurent Bardiaux , Marylise Fort , Benedicte Debiol , Daniele
3*
2*
2,5
2*
Morere , Françoise Huguet, MD , Christian Récher, MD-Ph.D. and Sarah Bertoli, M.D; Ph.D
1
Toulouse, France
2
France
3
Etablissement Français du Sang, Toulouse, France
4
Immunology, Toulouse Universitary Hospital, toulouse, France
5
2552 Effect of Pregnancy in Women with a History of Primary Immune Thrombocytopenia Considered As
Cured
Session: 311. Disorders of Platelet Number or Function: Poster II
1*
2,3*
1*
1*
Thibault Comont , Guillaume Moulis, MD, PhD , Karen Delavigne, MD , Pierre Cougoul, MD , Olivier Parant,
4*
4*
5
1*
MD, PhD , Beatrice Guyard Boileau, MD , Christian Récher, MD-Ph.D. , Daniel Adoue, MD, PhD and Odile
1*
Beyne Rauzy, MD, PhD
1
Toulouse, France
2
3
4
Department of Obstetrics and Gynecology, Paule de Viguier Hospital - CHU de Toulouse, Toulouse, France
France
5
1718 Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase
of the Disease in Routine Practice
Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and
Prognosis: Poster I
1*
1*
2,3*
4*
Sarah Bertoli, M.D; Ph.D , Suzanne Tavitian, M.D , Eric Delabesse, PharmD, PhD , Audrey Sarry , Françoise
4*
1,5
Huguet, M.D and Christian Récher, MD-Ph.D.
1
France
2
3
4
France
5
3576 Impact of Non Professional Physicians’ Characteristics on Medical Decision Making in Older Patients
with Acute Myeloid Leukemia
Health Services Research—Malignant Conditions
Session: 902. Health Services Research—Malignant Conditions: Poster II
1,2*
3,4*
5*
1*
Pierre Bories, MD , Sébastien Lamy, PhD , Celestine Simand , Sarah Bertoli, M.D; Ph.D , Sandra Malak,
6*
5*
7*
1,8
MD , Luc Mathieu Fornecker, MD, PhD , Stephane Moreau, MD , Christian Recher, MD, PhD and Antoine
9*
Nebout, PhD
1
France
2
Réseau régional de cancérologie ONCOMIP, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse,
France
3
Department of clinical pharmacology, Toulouse university hospital, Toulouse, France
4
Laboratory of Epidemiology and Analyses in public health (LEASP) - UMR 1027 Inserm, Toulouse III University,
Toulouse, France
5
Haematology, University Hospital, Strasbourg, France
6
Hopital Rene Huguenin-Institut Curie, Saint Cloud, FRA
7
Haematology, University Hospital, Limoges, France
8
9
UR 1303 ALISS,, INRA University Paris-Saclay, Ivry-sur-Seine, France
2138 Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma:
Primary Results of the IFM2014-04 Trial
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
1*
1*
1*
2*
Eileen Mary Boyle, MD, MSc , Marie-Odile Petillon, MD , Charles Herbaux, MD , Johanna Mimouni , Xavier
3
4*
5
6*
7*
Leleu , Lionel Karlin, MD , Chantal Doyen, MD , Marc Wetterwald, MD, PhD , Muriel Roussel, MD , Cyrille
8*
9*
10*
11*
12*
13*
Hulin , Bruno Royer, MD , Margaret Macro , Philippe Moreau , Karel Fostier, MD , Mamoun Dib ,
14*
15*
16*
17*
Sabine Brechignac, MD , Caroline Bureau , Gerald Marit, MD , Adrian Tempescul, MD , Marie Lorraine
18*
19*
20*
21*
22*
Chretien , Charles Zarnitsky , Cecile Fohrer, MD , Aurore Perrot, MD , Lotfi Benboubker, MD, PhD ,
23*
24*
25*
26*
27*
Laurent Voillat , Jean Valere Malfuson , Clara Mariette , Mourad Tiab , Sophie Rigaudeau , Arnaud
28*
29
30*
31*
32*
Jaccard, MD, PhD , Anne-Marie Stoppa , Laure Vincent , Jean Claude Eisenmann, MD , Laurent Frenzel ,
33*
34
35
36*
Bertrand Arnulf, MD , Mohamad Mohty, MD, PhD , Philippe Rodon, MD , Brigitte Kolb , Olivier Decaux,
37*
38*
1*
1*
1*
1*
MD, PhD , Pascal Godmer , David Beauvais , Benjamin Carpentier , Sarah Bonnet, MD , Thomas Longval ,
1*
39*
40
41*
42
Mathieu Dewevre , Hervé Avet-Loiseau , Michel Attal , Susanna Schraen, PharmD and Thierry Facon
1
Service des maladies du sang, Lille University Hospital, Lille, France
2
Departement de recherche clinique, Lille University Hospital, Lille, France
3
4
5
Department of Hematology, CHU Dinant Godinne UcL, Yvoir, Belgium
6
CHD Dunkerque, Dunkerque, France
7
Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France
8
Bordeaux Hospital University Center (CHU), Bordeaux, France
9
Department of Hematology, University Hospital, Amiens, France
10
Hopital Cote De Nacre, Caen Cedex 9, FRA
11
12
Uz Brussel, Brussel, BEL
13
Hématologie - CHU - Hôpital du Bocage, Angers, France
14
Hopital Avicenne, bobigny, France
15
Polyclinique Bordeaux Nord Aquitaine, Bordeaux Cedex, FRA
16
17
Hematology Department, CHU Brest, Brest, France
18
Hématologie Clinique CHU DIJON, Dijon, France
19
Hopital J Monod, Brest, France
20
HEMATOLOGY, CHU, Strasbourg, FRA
21
hematology department, university hospital, Vandoeuvre Les Nancy, France
22
23
Centre Hospitalier William Morey, Chalons-sur-Saone, France
24
Hôpital d'instruction des armées Percy, Paris Cedex 10, FRA
25
Hematology, Grenoble University Hospital, Grenoble, France
26
27
Service Hematologie, CHU Andre Mignot, Versailles, France
28
Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à
Dépôts, CHU Limoges, Limoges, France
29
Institut Paoli Calmettes, Marseille, France
30
CHU, Montpellier, FRA
31
Hematology Department, CH Mulhouse, Mulhouse, France
32
Hopital Necker, Paris, FRA
33
34
Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France
35
Centre Hospitalier, Perigueux, France
36
Hopital Robert Debre, Reims Cedex, France
37
Internal Medicine, University Hospital CHU Rennes, Rennes, France
38
Department of Hematology, Hospital, Bretagne atlantique, France
39
40
41
Department of biochemistry, Lille Universiy Hospital, Lille, France
42
Service des Maladies du Sang, Hopital Claude Huriez, Lille, France
1743 Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute
Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study
Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis
Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and
Prognosis: Poster I
1*
2
3*
4
5*
Laura Clement , Stefan Suciu, PhD , Isabelle Luquet, M.D , Alina Ferster, MD, PhD , Karima Yakouben, MD ,
6*
7*
8*
9*
Anne Uytterbroeck , Catherine Paillard, MD PhD , Nicolas Sirvent , Vitor Costa , Barbara De Moerloose,
10*
11
12*
13*
14*
MD , Francoise Mazingue , Emmanuel Plouvier, MD , Martine Munzer , Maryline Poirée , Odile Minckes,
15*
16*
17*
18*
19*
20*
MD , Frédéric Millot, MD , Dominique Plantaz , Caroline Piette , Frank Speleman, Prof , Hélène Cavé ,
21*
22*
23*
24
Jutte VanderWerff-tenBossch , Pierre Simon Rohrlich, MD PhD , Yves Bertrand , Yves Benoit and
25*
Geneviève Plat
1
CHU Toulouse, Toulouse, France
2
EORTC Headquarters, Brussels, Belgium
3
France
4
Dept. of Hémato-oncologie pédiatrique, Children's University Hospital Reine Fabiola, Brussels, Belgium
5
Robert Debre Hospital, AP-HP, Paris, France
6
U.Z. gasthuisberg, Leuven, Belgium
7
Pediatric Hematology, CHU Strasbourg, Strasbourg, France
8
Pediatric Hematology and oncology department, CHU Montpellier, Montpellier, France
9
Instituto Portugues de Oncologia - Centro do Porto, Porto, Portugal
10
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital,
Ghent, Belgium
11
hematology, CHRU Lille, Lille, France
12
pediatric hematology, CHRU Besançon, Besançon, France
13
CHU Reims, Reims, France
14
CHU Nice, Nice, France
15
Pediatric Oncology Hematology Department, CHU Caen, Caen, France
16
University Hospital, Poitiers, FRA
17
Department of Pediatric Hematology-Oncology,, CHU Grenoble, Grenoble, France
18
University Department of Pediatric Oncology, CHR Citadelle, Liège, Belgium
19
Center for Medical Genetics, Ghent University, Ghent, Belgium
20
Hôpital Robert Debré, AP-HP, Paris, France
21
U.Z. Gasthuisberg, Leuven, Belgium
22
Hematology-Pediatry, Besan??on, FRA
23
CHU Lyon, Lyon, France
24
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, University Hospital Ghent,
Ghent, Belgium
25
Department of Hematology, CHU Toulouse, Toulouse, France
2128 IFM2012-03
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
1
2*
3*
4*
5*
6*
Xavier Leleu , Guillemette Fouquet , Lionel Karlin, MD , Brigitte Kolb , Mourad Tiab , Carla Araujo ,
7
8
9*
10*
Nathalie Meuleman, MD, PhD , Jv Malfuson , Pascal Bourquard, MD , Pascal Lenain , Murielle Roussel,
11*
12*
13*
14*
15*
MD , Arnaud Jaccard, MD, PhD , Marie-Odile Petillon, MD , Karim Belhadj-Merzoug , Gerard Lepeu ,
16*
17*
18
19*
20*
Marie-Lorraine Chretien , Jean Fontan , Philippe Rodon, MD , Anna Schmitt, MD , Fritz Offner , Laurent
21*
22*
23*
24*
25*
Voillat , Sophie Cereja , Frederique Kuhnowski , Sophie Rigaudeau , Olivier Decaux, MD, PhD ,
26*
27*
28*
29*
Catherine Humbrecht-Kraut , Jamile Frayfer, MD , Olivier Fitoussi, MD , Damien Roos Weil , Jean Claude
30*
31*
32
33*
34
Eisenmann, MD , Veronique Dorvaux , Eric G. Voog, MD , Cyrille Hulin , Michel Attal , Philippe
35*
36
Moreau and Thierry Facon
1
2
Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France
3
Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France
4
Hopital Robert Debre, Reims Cedex, France
5
6
Centre Hospitalier de la côte basque, Bayonne, France
7
Hematology, Institut Jules Bordet, ULB, Brussels, Belgium
8
Dept. of Hematology, Hopital Percy, Clamart, France
9
Hopital Caremeau, Nimes, France
10
Centre Henri Becquerel, Rouen, France
11
HEMATOLOGY, IUCT ONCOPOLE, Toulouse, France
13
14
Service Hematologie, CHU Henri Mondor, Creteil, France
15
Service Hematologie, Centre Hospitalier H. Duffaut, Avignon, France
16
Hospital Bocage, Dijon, France
17
Service Hematologie, CHU Besancon, Besancon, France
18
19
Hematology Department, Institut Bergonie, Bordeaux, France
20
Ghent University Hospital, Ghent, Belgium
21
Department of Hematology, Hospital, Chalon sur saone, France
22
Service Hematologie, CH Francilien, Corbeil-Essones, France
23
Service Hematologie, Institut Curie, Paris, France
24
Service Hematologie, CHU Andre Mignot, Versailles, France
25
26
Service Onco-Hematologie, CH Louis Pasteur, Colmar, France
27
Hématologie, Meaux Hospital, Meaux, France
28
Polyclinique Bordeaux Nord-Aquitaine, Bordeaux, France
29
Service Hematologie, AP-HP Groupe Hospitalier Pitie-Salpetriere, Paris, France
30
Hematology Department, CH Mulhouse, Mulhouse, France
31
Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France
32
Hematology Department, Le Mans, Centre Jean Bernard, Le Mans, France
33
34
35
Hematology, University Hospital Hôtel Dieu, Nantes, France
36
12
3128 Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM)
Registry
Myeloproliferative Syndromes: Clinical
Session: 634. Myeloproliferative Syndromes: Clinical: Poster II
1
2*
3*
4*
Brigitte Dupriez, MD , Sylvie Chevret, MD, PhD , Jean-Christophe Ianotto, MD , Francoise Boyer, MD ,
5*
6*
7*
8*
Pascale Cony-Makhoul, MD , Gabriel Etienne, MD, PhD , Mathieu Wemeau, MD , Jérome Rey , Laurent
9*
10
3*
11
Knoops, MD, PhD , Jean-Loup Demory, MD , Eric Lippert, PhD , Francois Girodon, MD, PhD , Laurence
12*
13*
14*
15*
Legros, MD, PhD , Anne Vekhoff, MD , Stephane Courby, MD , Fabienne Vacheret, MD , Nathalie
16*
17*
18*
19*
Cambier, MD , Stephane Giraudier, MD, PhD , Suzanne Tavitian, M.D , Kamel Laribi, MD , Sandra
20*
21*
22*
23*
24*
Malak , Dana Ranta, MD , Fiorenza Barraco, MD , Isabelle Plantier, MD , Sophie Dupire , Marc Simon,
25*
26*
27*
28
29*
MD , Selim Corm, MD , Ahmad AL Jijakli, MD , Philippe Rodon, MD , Lise Willems, MD, PhD , Bohrane
30*
31*
32*
33*
Slama, MD , Ronan Le Calloch, MD , Pierre Morel, MD , Valerie Ugo, MD, PhD and Jean-Jacques
34
Kiladjian, MD, PhD
1
Service Hematologie Clinique, Centre hospitalier de Lens, Lens, France
2
Biostatistics department, Hôpital Saint-Louis, Paris, France
3
Centre Hospitalier Universitaire, Brest, France
4
Centre Hospitalier Universitaire, Angers, France
5
Centre Hospitalier Annecy-Genevois, Pringy, France
6
7
CH, Arras, France
8
Hematology Department, Institut Paoli Calmettes, Marseille, France
9
Cliniques Universitaires Saint-Luc and de Duve Institute, Université catholique de Louvain, Brussels, Belgium
10
Hôpitaux de l'Université Catholique de Lille, Lille, France
11
Hospital University Center (CHU), Dijon, France
12
Hematology department, Hopital Archet 1, CHU Nice, Nice, France
13
Hematology and Cellular Therapy, Saint Antoine Hospital, Paris, France
14
Hematology department, CHU Grenoble, Grenoble, France
15
CH, Perpignan, France
CHRU, Lille, France
17
Hôpital Henri-Mondor, Créteil, France
18
France
19
Centre Hospitalier, Le Mans, France
20
CHU Curie, Paris, France
21
Centre Hospitalier Universitaire, Nancy, Nancy, France
22
Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France
23
CH, Roubaix, France
24
CH, Bourg en Bresse, France
25
Centre Hospitalier, Valenciennes, France
26
Médipole de Savoie, Challes Les Eaux, France
27
CH Argenteuil, Argenteuil, France
28
29
Cochin Hospital, University Paris 5, Paris, France
30
CH, Avignon, France
31
CH, Quimper, France
32
33
Laboratoire Hematologie, CHU Angers, Angers, France
34
Hôpital Saint-Louis and Paris Diderot University, Paris, France
16
241 Final Analysis of Overall Survival from the First Trial
Type: Oral
Biomarkers
1
2
3
4
5
Thierry Facon , Meletios Dimopoulos , Angela Dispenzieri , John V. Catalano , Andrew Belch , Michele Cavo,
6*
7*
8*
9
10,11
12*
13*
MD , Antonello Pinto , Katja Weisel , Heinz Ludwig , Nizar J. Bahlis, MD , Anne Banos , Mourad Tiab ,
14
15
16*
17
18*
19*
Michel Delforge , Jamie D. Cavenagh , Catarina Geraldes , Je-Jung Lee , Christine Chen , Albert Oriol ,
20*
21
22
23
24
25*
Javier De La Rubia , Darrell White , Daniel Binder , Jin Lu , Kenneth C. Anderson , Philippe Moreau ,
26
27
28*
29
29*
Michel Attal , Jean-Paul Fermand , Hervé Avet-Loiseau , Annette Ervin-Haynes , Guang Chen , Vanessa
29*
30*
31*
Houck , Cyrille Hulin and Lofti Benboubker
1
Service des Maladies du Sang, Hopital Claude Huriez, Lille, France
2
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3
Mayo Clinic, Rochester, MN
4
Frankston Haematology and Oncology Center, Frankston, Australia
5
Cross Cancer Institute, Edmonton, AB, Canada
6
Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
7
Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale,
IRCCS, Napoli, Italy
8
University of Tuebingen, Tuebingen, Germany
9
Wilhelminen Cancer Research Institute, Department of Medicine, Center of Oncology, Hematology and
Palliative Care, Wilhelminenspital, Vienna, Austria
10
University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
11
University of Calgary, Calgary, AB, Canada
12
Centre Hospitalier de la Cote basque, Bayonne, France
13
14
Department of Hematology, UZ Leuven, Leuven, Belgium
15
Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United
Kingdom
16
Hospitals da Universadade de Combra, Combra, Portugal
17
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea,
The Republic of
18
Princess Margaret Cancer Centre, Toronto, ON, Canada
19
Hospital Germans Trias i Pujol, Barcelona, Spain
Hospital Universitari i Politècnic La Fe, Valencia, Spain
21
QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada
22
Kantonsspital Winterthur, Winterthur, CHE
23
Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China
24
Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
25
University of Nantes, Nantes, France
26
27
Hopital Saint-Louis, Paris, France
28
Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France
29
Celgene Corporation, Summit, NJ
30
31
20
3569 Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: HighDose Cyclophosphamide Versus Plerixafor. on Behalf of IFM
Health Services Research—Malignant Conditions
Session: 902. Health Services Research—Malignant Conditions: Poster II
1*
2*
3*
4*
5
Zoe van de Wyngaert , Nabih Azar, MD , Pascal Lenain , Margaret Macro , Jean-Henri Bourhis, MD, PhD ,
6
7*
8*
9*
Laurent Garderet, MD , Arnaud Jaccard, MD, PhD , Lionel Karlin, MD , Christine Giraud , Stéphanie Guidez,
10*
11*
12*
13*
14*
MD , Benjamin Hebraud , Muriel Roussel, MD , Gerald Marit, MD , Cyrille Hulin, MD , Eric Deconinck,
15
16
17*
18*
19*
20
MD, PhD , Michel Attal , Philippe Moreau , Denis Caillot , Samuel Limat, PhD , Xavier Leleu and Marie21*
Lorraine Chretien
1
Service des Maladies du sang, hopital claude hurriez, CHRU lille, Lille, France
2
Service d'Hématologie Clinique, Hôpital de la Pitié-Sâlpétrière, PARIS CEDEX 13, France
3
Centre Henri Becquerel, Rouen, France
4
Haematology Department, Caen University Hospital, Caen, France
5
Division of Hematology, Institut Gustave Roussy, Villejuif, France
6
Hematology Department, CHU St Antoine, Paris, France
7
8
9
CHU de POITIERS, Poitiers, FRA
10
Oncologie hématologique et thérapie cellulaire, CHU Poitiers, Poitiers, France
11
CHU Toulouse, TOULOUSE, FRA
12
Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France
13
14
hematology department, university hospital, bordeaux, France
15
Hematology, INSERM UMR1098 - CHU Jean Minjoz, Besancon, France
16
17
18
19
Pharmacy, CHRU Besancon, Université de Bourgogne Franche -comté, Besançon, France
20
21
Hospital Bocage, Dijon, France
3476 Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective
Analysis of the National SFGM-TC Registry
Clinical Allogeneic Transplantation: Results
Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
1,2
2,3*
4
Franck-Emmanuel Nicolini, MD, PhD , Valerie Coiteux, MD , Gerard Socie, MD, PhD , Didier Blaise, MD,
5
6
7*
8*
PhD , Eric Deconinck, MD, PhD , Patrice Chevallier, MD, PhD , Pierre Simon Rohrlich , Stephanie Nguyen, MD,
9*
10
11
12*
PhD , Thierry Lamy, MD PhD , Jean-Henri Bourhis, MD, PhD , Marie-Thérèse Rubio, MD, PhD , Felipe Suarez,
13
14*
15
16*
17
MD, PhD , Jerome Cornillon, MD , Gandhi Damaj, MD , Natacha Maillard, MD , Noel Milpied, MD PhD ,
18*
19
20*
21*
Patrice Ceballos, MD , Mohamad Mohty, MD, PhD , Claude-Eric Bulabois, MD , Bruno Lioure, MD , Gerard
22*
23
24
25*
26*
Michel, MD , Norbert Ifrah , Yves Beguin, MD, PhD , Anne Huynh, MD , Nathalie Contentin, MD ,
27
28*
29*
Jacques-Olivier Bay, MD, PhD , Yves Bertrand, MD, PhD , Yves Perel, MD , Jean-Hugues Dalle, MD, PhD,
30
31*
32*
33*
Prof. , Gaelle Guillerm, MD , jean-Valere Malfuson, MD , Aude Marie-Cardine, MD , Mauricette Michallet,
2,34
35*
36*
34*
MD, PhD , Nicole Raus, Data Manager , Marie Balsat, MD , Helene Labussiere, MD , Regis Peffault De
4*
37
Latour, MD, PhD and Ibrahim Yakoub-Agha, MD, PhD
1
Centre Hospitalier Lyon Sud, Hématologie clinique 1G, Pierre Bénite, France
2
Fi-LMC group, Pessac, France
3
Hematology, CHU de Lille, Lille, France
4
Hematology / Transplantation, Saint Louis Hospital, Paris, France
5
Programme de Transplantation &Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille,
6
7
8
Pediatric Oncology, CHU Nice, Nice, France
9
Department of hematology, Pitie Salpetriere Hospital, Paris, France
10
INSERM U917, CHU Pontchaillou, Rennes, France
11
Gustave Roussy Cancer Center, Villejuif, France
12
13
Hôpital Universitaire Necker-Enfants Malades, Paris, France
14
Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France
15
Hematology Department, CHU Caen, Caen, France
16
Bone Marrow Transplant Unit Clinical Hematology, Hopital La Miletrie, Poitiers, France
17
Service d'Hématologie et de Thérapie Cellulaire, CHU Haut-Leveque and University of Bordeaux, Bordeaux,
France
18
Hematology, CHU Lapeyronie, Montpellier, France
19
20
Hematology, CHU Grenoble, Grenoble, France
21
Hematology and Oncology, Hopital Hautepierre, Strasbourg, France
22
Hematology, CH Timone, Marseille, France
23
Hematology, Angers University Hospital, Angers, France
24
Hematology, University and CHU of Liege, Liege, Belgium
25
Institut Universitaire du Cancer, Oncopole IUCT, Toulouse, France
26
Hematology, Centre Henri Becquerel, Rouen, France
27
Hematology department, CHU Clermont Ferrand, Clermont Ferrand, France
28
Department of Pediatric Hematology and Oncology, University Hospital of Lyon, Lyon, France
29
Pediatric Hematology department, CHU Pellegrin, Bordeaux, France
30
Pediatric Hematology Department, Robert Debre Hospital, Paris, France
31
Hematology and Oncology, CH Augustin Morvan, Brest, France
32
Military Hospital, Clamart, France
33
Pediatric Hematology department, Charles Nicolle Hospital, Rouen, France
34
35
SFGM-TC, Lyon, France
36
Hématologie Clinique, Lyon-Sud Hospital, Pierre Benite, France
37
Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France
3696 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective
Observational Study from the Acute Leukemia French Association (ALFA) Group
Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections:
Poster III
1
1*
1*
Mauricette Michallet, MD, PhD , Mohamad Sobh, PharmD , Alexandre Deloire, CRA , Emmanuel Raffoux,
2*
3*
4*
5
6*
MD , Stephane de Botton , Denis Caillot , Oumedaly Reman, MD , Stephane Girault, MD , Celine Berthon,
7*
8*
9*
10*
11
MD, PhD , Francoise Huguet, MD , Stephane Lepretre , Thibaut Leguay, MD , Sylvie Castaigne, MD, PhD ,
12*
13*
14*
15*
Bruno Royer, MD , Cecile Pautas, MD , Jean-Valere Malfuson, MD , Jose Fernandes, MD , Thomas Prebet,
16*
17*
18*
19
20*
MD , Thorsten Braun, MD , Lauris Gastaud, MD , Felipe Suarez, MD, PhD , Aline Schmidt, MD , Remy
21
22*
23*
24*
Gressin, MD , Jacques Delaunay, MD , Caroline Bonmati, MD , Karine Celli-Lebras, CRA , Mohamed El1*
2
1
25*
Hamri, CRA , Herve Dombret, MD, PhD , Xavier Thomas, MD, PhD and Anne Bergeron, MD, PhD
1
2
Hematology Department, Saint Louis Hospital, Paris, France
3
Institut Gustave Roussy, Villejuif, France
4
5
Hematology, CHU Caen, Caen, France
6
Hematology, Limoges university hospital, Limoges, France
7
Hematology, CHRU de Lille, Lille, France
8
Hématologie, Toulouse Cancer University Institute, Toulouse, France
9
Hematology, Henri Becquerel Anti-Cancer Center, Rouen, France
10
Hematology, CHU Bordeaux, Pessac, France
11
Hematology, Hopital Mignot, Le Chesnay, France
12
13
Hematology, Henri Mondor Hospital, Creteil, France
14
Hematology, Military Hospital, Clamart, France
15
Hematology, Centre Hospitalier Valenciennes, Valenciennes, France
16
Hematology, Institut Paoli-Calmettes, Marseille, France
17
Hematology, Avicenne Hospital, APHP, Bobigny, France
18
Hematology, Centre Antoine Lacassagne, Nice, France
19
20
Hematology, CHU angers, Angers, France
21
22
Hematology, Nantes University Hospital, Nantes, France
23
Hematology, CHU Nancy, Nancy, France
24
ALFA group, Paris, France
25
Pneumology, Saint Louis Hospital, Paris, France
????
3450 Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a
French Multicenter Study of 386 Patients from Lysa Centers
Session: 731. Clinical Autologous Transplantation: Results: Poster II
1*
2*
3*
Sylvain Chantepie, MD , Emmanuelle Tchernonog, MD , Frederic Peyrade, MD , Marie-Virginie Larcher,
4*
5*
6*
7*
8*
MD , Momar Diouf, MD , Luc Mathieu Fornecker, MD, PhD , Roch Houot, MD, PhD , Thomas Gastinne, MD ,
9
10*
11*
12*
Carole Soussain, MD, PhD , Sandra Malak, MD , Olivier Tournilhac, MD, PhD , Caroline Delette , Ahmad
13*
1*
14*
15*
Ibrahim , Anne-Claire Gac, MD , Jean-Pierre Vilque, MD , Mohamed Amine Bekadja , Rene-Olivier
16*
17
18*
19*
Casasnovas, MD , Remy Gressin, MD , Arnaud Jaccard, MD, PhD , Benjamin Carpentier , Reda Garidi,
20*
21*
22*
23*
24*
MD , Bachra Choufi, MD , Stéphanie Guidez, MD , Adrian Tempescul, MD , Adrien Chauchet, MD ,
25
26
27*
Emmanuel Gyan, MD, PhD , Ibrahim Yakoub-Agha, MD, PhD , Krimo Bouabdallah, MD , Eric Durot,
28*
29
MD and Gandhi Damaj, MD
1
Institut d'Hématologie de Basse-Normandie, CHU, Caen, France
2
Department of Clinical Hematology, University Hospital Montpellier, Montpellier, France
3
Hematology Department, Centre Antoine Lacassagne, Nice, France
4
Hematology, Toulouse University Hospital, Toulouse, France
5
Amiens University hospital, Amiens, France
6
7
Hematology, University hospital, Rennes, France
8
9
Dept. of hematology, Curie Institute, Hôpital René Huguenin, Saint-Cloud, France
10
Hopital Rene Huguenin-Institut Curie, Saint Cloud, FRA
11
Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7283, CIC501,
Clermont-Ferrand, Clermont Ferrand, France
12
Oncopole Hopital Sud, Amiens, FRA
13
Makassed General Hospital, Beirut, LBN
14
Institut d'Hématologie de Basse-Normandie, Centre François Baclesse, Caen, France
15
Hematology and Cell Therapy, Etablissement Hospitalier Universitaire (EHU) 1st November, Oran, Algeria
16
Hematology, University Hospital, Dijon, France
17
18
19
20
Hospital, Saint Quentin, France
21
Service d'Hématologie, CH Boulogne sur Mer, BOULOGNE SUR MER, France
22
Oncologie hématologique et thérapie cellulaire, CHU Poitiers, Poitiers, France
23
Hematology, Brest University Hospital, Brest, France
24
Hematology, CHU, Besancon, France
25
Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France
26
27
Haematology, CHU de Bordeaux, Bordeaux, France
28
Department of Hematology, Centre Hospitalier Universitaire, Reims Cedex, FRA
29
895 Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a
Randomized Trial (APL2006) By the French Belgian Swiss APL Group
Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation
Type: Oral
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: APL and
other AML Specific Subsets
1
2*
3
4*
Lionel Ades, MD, PhD , Emmanuel Raffoux, MD , Olivier Spertini , Agnès Guerci, MD, PhD , Christian Recher,
5
6*
7
8*
9
MD, PhD , Denis Guyotat , Eric Deconinck, MD, PhD , Thierry Lamy De La Chapelle , Xavier Thomas, MD, PhD ,
10
11,12
13*
14,15*
Dominique Bordessoule, MD, PhD , Norbert Vey , Stephane de Botton , Arnaud Pigneux, MD
, Denis
16*
17
18*
19
Caillot , Jean-Yves Cahn, MD , Patrice Chevallier, MD, PhD , Jean-Francois Lambert, MD , Claude Gardin,
20*
21*
22*
23*
24
MD, PhD , Herve Dombret , Julie Lejeune , Sylvie Chevret and Pierre Fenaux, MD, PhD
1
Service d’Hématologie Séniors,, St Louis hospital, University Paris 7, Paris, France
2
Hematology Department, Saint-Louis Hospital, Paris, France
3
Hematology, CHUV, Lausanne, Switzerland
4
Hématologie Clinique, CHU Nancy-Brabois, Vandoeuvre, France
5
France
6
Hematology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France
7
8
Universite de Rennes, Rennes Cedex 9, FRA
9
10
Hematology, Limoges University Hospital, Limoges, France
11
Department of Hematology, Institut Paoli Calmettes, Marseille, France
12
Aix Marseille Université, Marseille, France
13
Institut Gustave Roussy, Villejuif, France
14
Hôpitaux du Haut Lévéque CHU Bordeaux, Pessac, France
15
INSERM UMR 1035, Bordeaux University, Bordeaux, France
16
17
18
19
Hospital of Nyon, Nyon, Switzerland
20
Hematology Department, Avicenne Hospital, APHP, University Paris 13, Bobigny, France
Hematology, Hôpital Saint-Louis, Paris, France
22
Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
23
Statistics St-Louis Hospital, Paris 7, Paris, France
24
Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
21
4612 Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell
Leukemia (pPCL): Final Results of a Prospective Study of IFM Group
Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to
Disease Recurrence: Poster III
1*
2*
3*
4*
5*
Bruno Royer, MD , Momar Diouf , Murielle Roussel , Lionel Karlin, MD , Cyrille Hulin , Bertrand Arnulf,
6*
7*
8*
9*
10*
11*
MD , Margaret Macro , Sylvie Cailleres , Annie Brion, MD , Sabine Brechignac, MD , Karim Belhadj, MD ,
12*
13*
14*
15*
16
Marie Lorraine Chretien , Marc Wetterwald, MD, PhD , Carine Chaleteix , Mourad Tiab , Xavier Leleu ,
17*
18
19*
20*
Laurent Frenzel , Laurent Garderet, MD , Sylvain Choquet, MD , jean Gabriel Fuzibet , Charles Dauriac,
21*
22*
23*
24
25*
MD , luc-Matthieu Fornecker , Lotfi Benboubker, MD, PhD , Thierry Facon , Philippe Moreau , Hervé
26*
27*
28
Avet-Loiseau , Stephane Minvielle and Jean Pierre Marolleau, MD, PhD
1
2
University Hospital, Amiens, France
3
Institut Universitaire du Cancer, toulouse, France
4
5
6
7
Haematology Department, Caen University Hospital, Caen, France
8
Centre hospitalier, aix en Provence, France
9
Hopital Jean Minjoz, Besancon, France
10
Hopital Avicenne, bobigny, France
11
CHU Henri Mondor, Creteil, France
12
CHRU Dijon, Dijon, France
13
CHD Dunkerque, Dunkerque, France
14
university hospital, Clermont Ferrand, France
15
16
17
Hopital Necker, Paris, FRA
18
19
Department of Clinical Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris,
France
20
University hospital, Nice, France
21
Hematology, CHU Rennes, Rennes, France
22
university hospital, strasbourg, France
23
24
25
26
Institut Universitaire du Cancer and University Hospital, Unité de Génomique du Myélome, Toulouse, France
27
Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche
Thérapeutique de l’Université de Nantes (IRT-UN), Nantes, France
28
Unit of Hematology, University Hospital, Amiens, France
4018 Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute
Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study
Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
1*
2*
3*
Patrice Chevallier, MD, PhD , Sylvain Chantepie, MD , Françoise Huguet, MD , Emmanuel Raffoux, MD,
4*
5
6*
7*
8*
PhD , Xavier Thomas, MD, PhD , Thibaut Leguay, MD , Tony Marchand, MD , Francoise Isnard, MD PhD ,
9*
10*
11*
12*
Aude Charbonnier , Sebastien Maury, MD, PhD , Maria-Pilar Gallego-Hernanz, MD , Nelly Robillard, PhD ,
1*
13*
1*
14*
Thierry Guillaume, MD, PhD , Pierre Peterlin, MD , Alice Garnier, MD , Fanny Rialland, MD , Claire Le
15*
16
16
Houerou , David M Goldenberg, ScD, MD , William Wegener, MD, PhD , Marie C Bene, PharmSciD,
17*
18
PhD and Herve Dombret, MD
1
2
Institut d'Hématologie de Basse-Normandie, CHU, Caen, France
3
France
4
Hematology Department, Saint Louis Hospital, Paris, France
5
CHU, Lyon, France
6
Hematology, CHU Bordeaux, Pessac, France
7
Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France
8
9
Hematology department, Institut Paoli Calmettes, Marseille, France
10
Hopital Henri Mondor, Creteil, FRA
11
Hematology Department, CHU, Poitiers, France
12
Hematology Laboratory, Nantes University Hospital, Nantes, France
13
HOPITAL HOTEL DIEU ET HME, NANTES CEDEX 1, FRA
14
Oncopediatrics Department, Nantes University Hospital, Nantes, France
15
Hematology Department, CHU, Nantes, France
16
Immunomedics, Inc., Morris Plains, NJ
17
Departement of Immunology, Centre Hospitalier Universitaire, Nantes, France
18
Hopital Saint Louis, Paris, France
3470 Triage Scoring System Based on Early Post-Transplant Complications for Patients with Myelodysplastic
Syndrome Requiring ICU after Allo-HCT: An SFGM-TC Study
1*
2*
3
4
5
Alexis Caulier , Elodie Drumez , Marie Robin, MD, PhD , Didier Blaise, MD, PhD , Yves Beguin, MD, PhD ,
6
7*
8
Mauricette Michallet, MD, PhD , Patrice Chevallier, MD, PhD , Jacques-Olivier Bay, MD, PhD , Stéphane
9*
10*
11*
12*
Vigouroux, MD , Yohan Desbrosses , Jérôme Cornillon, MD , Stephanie Nguyen, MD, PhD , Regis Peffault
13*
14*
15*
16*
De Latour, MD, PhD , Charles Dauriac, MD , Bruno Lioure, MD , Pierre Simon Rohrlich , Martin Carré,
17*
18
19*
20
21*
MD , Jean-Henri Bourhis, MD, PhD , Anne Huynh, MD , Felipe Suarez, MD, PhD , Federico Garnier, MD ,
22*
23
Alain Duhamel, MD, PhD and Ibrahim Yakoub-Agha, M.D.- PhD
1
Hematology and cellular therapy, CHU Amiens Sud, Amiens Cedex 1, France
2
Santé publique : épidémiologie et qualité des soins, Université de biostatistiques - CHU Lille, Lille, France
3
Hematology / Transplantation, Saint-Louis Hospital, Paris, France
4
5
6
Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France
7
8
9
University Hospital of Bordeaux, Bordeaux, France
10
Department of hematology, CHU Jean Minjoz, Besançon, France
11
Department of Hematology, Saint-Etienne University Hospital, Saint-Etienne, France
12
13
Hematology / Transplantation, Saint Louis Hospital, Paris, France
14
15
Hematology and Oncology, Hopital Hautepierre, Strasbourg, France
16
Pediatric Oncology, CHU Nice, Nice, France
17
Department of Hematology, CHU Grenoble, Grenoble, France
18
19
France
20
21
agence de la biomédecine, Saint Denis, France
22
Santé publique : épidémiologie et qualité des soins, Université de biostatistiques - CHRU Lille, Lille, France
23
Hematological department, Lille University Hospital, Lille, France
3920 Unique Long Non-Coding RNA Expression Signature in ETV6/RUNX1-Driven B-Cell Precursor Acute
Lymphoblastic Leukemia
Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation
Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic
Regulation: Poster III
1,2*
2,3*
1*
1*
4
Farzaneh Ghazavi , Barbara De Moerloose, MD , Wouter Van Loocke , Annelynn Wallaert , Alina Ferster ,
5*
6*
7*
8*
Marleen Bakkus, PhD , Genevieve Plat, MD , Eric Delabesse, PharmD, PhD , Anne Uyttebroeck , Filip Van
9*
9*
1,3*
Nieuwerburgh, PharmD, Prof , Dieter Deforce, PharmD, Prof , Nadine van Roy, MD, Prof , Frank Speleman,
1,3*
10
2,3*
1,3*
Prof , Yves Benoit , Tim Lammens and Pieter van Vlierberghe, Prof
1
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
2
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital,
Ghent, Belgium
3
Cancer Research Institute Ghent (CRIG), Ghent, Belgium
4
Department of Hemato-Oncology, HUDERF, Brussels, Belgium
5
Department of Hematology, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium
6
Department of Hematology, CHU Toulouse, Toulouse, France
7
8
Department of Pediatric Hemato-Oncology, University Hospital Leuven, Leuven, Belgium
9
Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium
10
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, University Hospital Ghent,
Ghent, Belgium
196 The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the
Clinical Classification of Multiple Myeloma
Myeloma: Biology and Pathophysiology, excluding Therapy
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Prognostic Factors
1
2*
3*
1*
Brian A Walker, PhD , Mehmet K. Samur, PhD , Konstantinos Mavrommatis , Cody Ashby, PhD , Christopher
1*
4*
5*
1*
1*
P Wardell, PhD , Maria Ortiz, PhD , Fadi Towfic , Caleb K. Stein, MS , Michael A Bauer, PhD , Michael
5*
6*
5*
4*
7,8*
Amatangelo, PhD , Giovanni Parmigiani, PhD , Zhinuan Yu, PhD , Matthew Trotter , Hervé Avet-Loiseau ,
9
10
5*
10
Graham H Jackson, MD, PhD , Kenneth C. Anderson , Anjan Thakurta, Ph.D. , Nikhil C. Munshi, MD and
1
Gareth J Morgan, MD, PhD
1
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
2
The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston,
MA
3
Celgene Corporation, San Francisco, CA
4
Celgene Institute for Translational Research Europe, Celgene Corporation, Seville, Spain
5
Celgene Corporation, Summit, NJ
6
Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
7
Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale,
Toulouse, France
8
9
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
10
4230 Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude
Between 2010 and 2013
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results
from Retrospective/Observational Studies
Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin
Lymphomas)—Results from Retrospective/Observational Studies: Poster III
1*
1*
2*
3*
4*
Inès Boussen , Caroline Algrin, MD , Julien Rossignol, MD , Eric Durot, MD , Sarah Guenounou , Antoine
5*
6*
7
8
9
Bonnet , Jeremy Delage, MD , Emmanuel Gyan, MD, PhD , Fontanet Bijou, MD , Noel Milpied, MD , Adrien
10*
11*
12
13*
Chauchet, MD , Adrien Tempescul, MD , Gandhi Damaj, MD , Arnaud Jaccard, MD, PhD , Jerome
14*
15
16
1*
Cornillon, MD , Norbert Ifrah , Veronique Leblond and Sylvain Choquet, MD
1
Department of Clinical Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris,
France
2
Department of Hematology, Necker Children's hospital, APHP, Paris, France
3
Department of Hematology, Centre Hospitalier Universitaire, Reims Cedex, FRA
4
France
5
Department of Hematology, University of Nantes, Nantes, France
6
CHU Lapeyronie, Département d`Hématologie Clinique, Montpellier, FRA
7
Department of Clinical Hematology, CHRU de Tours, Tours, France
8
Institut Bergonie, Bordeaux, France
9
Service d’Hematologie Clinique et Therapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France
10
Hematology, CHU, Besancon, France
11
Haematology, University Hospital, Brest, France
12
13
14
Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France
15
16
Department of Clinical Hematology, AP-HP Hôpital Pitié-Salpêtrière, Paris, France
2555 Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune
Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists
1*
2*
3*
Matthieu Mahevas, MD, PhD , Sandrine Van Eeckhoudt, MD , Guillaume Moulis, MD, PhD , Christine
4*
5*
6*
7*
8*
Dosquet, MD, PhD , Marc Michel, MD, PhD , Nicolas Limal, MD , Laetitia Languille , Sawsaneh Alkaeir, MD ,
9*
10*
11*
12*
Philippe Bierling, MD, PhD , Antoine Dossier, MD , Frédéric Duriez, MD , Lionel Galicier, MD , Anne-Sophie
13*
14*
15*
16*
Morin, M.D , Jérôme Tamburini, MD, PhD , Driss Chaoui, MD , Didier Bouscary, MD, PhD , Ahmad AL
17*
18*
19*
20*
Jijakli, MD , Mehdi Khellaf, MD , Ioana Vaida, MD , Bertrand Godeau, MD, PhD and Christine
21
Chomienne, MD, PhD
1
Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC
University, Créteil, France
2
Internal Medicine., French Referral Center for Adult's Immune Cytopenia. Henri Mondor. AP-HP. UPEC
University., Créteil, France
3
4
Service de Biologie Cellulaire, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint Louis, INSERM
UMR_S1131, Institut Universitaire d'Hématologie, Paris, France, Paris, France
5
Henri Mondor Hospital, Assistance Publique Hopitaux de Paris, Paris XII universi, Creteil, FRA
6
Internal Medicine., French Referral Center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC
7
French Referral center for Audlt's Immune Cytopenia. henri Mondor Hospital. UPEC University., Créteil, France
8
UMRS-1131, INSERM Hôpital Saint Louis, Paris, France
9
Internal Medicine, French Referral center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC
10
Department of internal Medicine, Hôpital Bichat, Paris, France
Oncology - Hematology, Les Hôpitaux de Chartres., Chartres, France
12
St-Louis University Hospital, Paris, France
13
Department of Internal Medicine, Hopital Jean Verdier, Bondy, France
14
Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
15
Hematology, CH Victor Dupouy, Argenteuil, France
16
Hematology Department, Cochin University Hospital, AP-HP, Paris, France
17
CH Argenteuil, Argenteuil, France
18
Henri Mondor Hospital, AP-HP, UPEC University, Creteil, France
19
Hematology, CH Pontoise, Pontoise, France
20
Internal Medicine, French Referral Center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC
21
UMRS-1131, INSERM Hopital Saint-Louis, Paris, France
11
3485 Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLAMismatched Donors for Hodgkin’s Lymphoma: A Study By the SFGM-TC (Francophone Society of Bone
Marrow Transplantation and Cellular Therapy)
1*
2*
3*
4*
Jordan Gauthier, MD , Luca Castagna, MD , Federico Garnier, MD , Thierry Guillaume, MD, PhD , Gerard
5
6*
7*
8
Socie, MD, PhD , Sebastien Maury, MD, PhD , Natacha Maillard, MD , Reza Tabrizi, MD , Tony Marchand,
9*
10*
11*
12
13*
MD , Jean Valere Malfuson , Anne-Claire Gac, MD , Emmanuel Gyan, MD, PhD , Melanie Mercier, MD ,
14
15*
16*
17*
Yves Beguin, MD, PhD , Jeremy Delage, MD , Pascal Turlure, MD , Ambroise Marçais, MD , Stephanie
18*
19*
20*
21*
Nguyen, MD, PhD , Remy Dulery, MD , Jacques Olivier Bay, MD , Anne Huynh, MD , Etienne Daguindau,
22*
23*
24
25*
MD , Caroline Régny , Mauricette Michallet, MD, PhD , Regis Peffault De La Tour, MD, PhD , Ibrahim
26
27
Yakoub-Agha, MD, PhD and Didier Blaise, MD, PhD
1
CHRU Lille Hopital Huriez, Lille, France
2
Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
3
agence de la biomédecine, Saint Denis, France
4
5
St-Louis Hospital, Paris, France
6
Hopital Henri Mondor, Creteil, FRA
7
8
Hematology, University Hospital of Bordeaux, Pessac, France
9
Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France
10
Hôpital d'instruction des armées Percy, Paris Cedex 10, FRA
11
CHU Caen, Caen, France
12
13
Haematology, CHU Angers, Angers, France
14
15
CHU Lapeyronie, Département d`Hématologie Clinique, Montpellier, FRA
16
Hematology, CHU Limoges, Limoges, France
17
Service d’hématologie and Imagine Institute, Necker Hospital, Paris, France
18
19
Hematology and Cellular Therapy, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France
20
Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
21
22
Hematology Department, Besançon University Department, Besançon, France
23
Department of Hematology, University CHU Grenoble, Grenoble, France
24
25
Hematology - Bone Marrow Transplantation, Hopital St Louis, Paris, France
26
27
903 Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with
Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial
Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Type: Oral
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Clinical Trials of Novel Drugs
and Combinations in AML
1
2
3*
4
5
Farhad Ravandi, MD , Ellen K. Ritchie, MD , Hamid Sayar, MD , Jeffrey E. Lancet, MD , Michael Craig, MD ,
6
7
8
9
Norbert Vey, MD, PhD , Stephen A. Strickland , Gary J. Schiller, MD , Elias J. Jabbour, MD , Harry P. Erba, MD,
10
11*
12
13
PhD , Arnaud Pigneux, MD , Heinz-August Horst, MD, PhD , Christian Recher, MD, PhD , Virginia M. Klimek,
14
15
16
17
17*
MD , Jorge E. Cortes, MD , Gail J. Roboz , Adam R. Craig, MD, PhD , Renee Ward, MD, PhD , Jennifer Smith,
17*
18
19
PhD , Hagop M. Kantarjian, MD and Robert K. Stuart, MD
1
University of Texas MD Anderson Cancer Center, Houston, TX
2
Weill Cornell Medical Center, New York, NY
3
Indiana University Cancer Center, Indianapolis, IN
4
Moffitt Cancer Center, University of South Florida, Tampa, FL
5
West Virginia University, Morgantown, WV
6
Institut Paoli-Calmettes, Marseille, France
7
Vanderbilt-Ingram Cancer Center, Nashville, TN
8
University of California Los Angeles, Los Angeles, CA
9
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
10
Division of Hematology and Oncology, University of Alabama, Birmingham, AL
11
Hôpital Haut Lévêque-CHU de Bordeaux, Pessac Cedex, France
12
II. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus, Kiel, Germany
13
Hôpital Purpan-CHU de Toulouse, Toulouse, France
14
303 East 60th Street Apt 27I, Memorial Sloan Kettering Cancer Center, New York City, NY
15
University of Texas M.D. Anderson Cancer Center, Houston, TX
16
Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New
York, NY
17
Sunesis Pharmaceuticals, Inc., South San Francisco, CA
18
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
19
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
4637 Extending Autologous Hematopoietic Stem Cell Transplantation As First Line Treatment in Multiple
Myeloma Patients with Severe Renal Impairment: A Retrospective Study of the Francophone Society of Stem
Cell Transplantation and Cellular Therapy (SFGM-TC)
Session: 731. Clinical Autologous Transplantation: Results: Poster III
1*
2*
3
4*
5*
Karine Augeul-Meunier, MD , Denis Caillot , Anne-Marie Stoppa , Lionel Karlin, MD , Lofti Benboubker ,
6*
7
8*
Natacha Maillard, MD , Mohamad Mohty, MD, PhD , Ibrahim Yakoub-Agha, MD , Jacques-Olivier Bay, MD,
9
10*
11*
12*
13*
PhD , Caroline Bonmati, MD , Claude-Eric Bulabois, MD , Anne Huynh, MD , Melanie Mercier, MD ,
14*
15*
1*
Laurent Frenzel, MD, PhD , Hervé Avet-Loiseau and Jerome Cornillon, MD
1
Hematology department, Institut de Cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France
2
3
4
5
6
7
8
Hematology, Lille, France
9
10
11
12
Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France
13
Haematology, CHU Angers, Angers, France
Department of Clinical Hematology, Hopital Necker, AP-HP, Paris, France
15
14
1162 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following
Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and
Myelodysplastic Syndrome
Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence
Type: Oral
Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to
Disease Recurrence: Immunotherapy to Prevent or Treat Relapse After Transplantation
1*
2
3
4*
Thierry Guillaume, MD, PhD , Ibrahim Yakoub-Agha, M.D.- PhD , Reza Tabrizi, MD , Cecile Borel, MD , Patrice
1*
2*
5*
1*
Chevallier, MD, PhD , Leonardo Magro, MD , Stéphane Vigouroux, MD , Pierre Peterlin, MD , Alice Garnier,
1*
6*
7*
8
1*
MD , Marie-Thérèse Rubio, MD, PhD , Anne Huynh, MD , Noel Milpied, MD PhD , Philippe Moreau and
9
Mohamad Mohty, MD, PhD
1
2
Hematological department, Lille University Hospital, Lille, France
3
4
Hematology, Toulouse University Hospital, Toulouse, France
5
University Hospital of Bordeaux, Bordeaux, France
6
7
Department Hématologie, Hôpital de Purpan, Toulouse, France
8
France
9
Hematology, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France
145 Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger
Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the
Lysa/Goelams Group
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Type: Oral
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Therapeutic
Approaches to Mantle Cell Lymphoma
1,2*
3
4*
5*
Steven Le Gouill, MD, PhD , Catherine Thieblemont, MD, PhD , Lucie Oberic, MD , Anne Moreau, MD ,
6*
7
8*
9
Krimo Bouabdallah, MD , Emmanuel Gyan, MD, PhD , Gandhi Damaj , Vincent Ribrag, MD , Pierre Feugier,
10*
11*
12*
13
MD, PhD , Olivier Casasnovas, MD , Hacene Zerazhi, MD , Corinne Haioun, MD, PhD , Hervé Tilly, MD,
14
15*
16*
17
PhD , Olivier Tournilhac, MD, PhD , Herve Maisonneuve, MD , Philippe Solal-Celigny, MD , Luc Mathieu
18*
19
20
21
Fornecker, MD, PhD , Eric W Van Den Neste, MD, PhD , Danielle Canioni, MD , Gilles Salles, MD, PhD ,
22
23*
24
25*
Thierry Lamy, MD PhD , Marie-Christine Bene, PharmD , Remy Gressin, MD and Olivier Hermine, MD, PhD
1
2
CHU de Nantes, INSERM UMR 892 équipe 10, Nantes, France
3
Hôpital Saint-Louis, Paris, France
4
Department of Hematology, Purpan University Hospital, Toulouse, France
5
Department of Pathology, Nantes University Hospital, Nantes, France
6
Haematology, CHU de Bordeaux, Bordeaux, France
7
8
CHU d'Amiens, Amiens, France
9
Gustave Roussy cancer campus, Villejuif, France
10
CHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France
11
Hematology Department, Hopital Le Bocage, CHU Dijon, Dijon, France
12
hematology, CHG Avignon, Avignon, France
13
Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
INSERM U918, Centre Henri Becquerel, Rouen, France
15
Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7283, CIC501,
Clermont-Ferrand, Clermont Ferrand, France
16
Oncology and Hematology Department, CH, La Roche-sur-Yon, France
17
Centre Jean Bernard, Le Mans, France
18
19
Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
20
Pathology Department, Hopital Necker, Paris, France
21
Hematologie, Hospices Civils de Lyon - Université de Lyon - UMR CNRS5239, Pierre-Benite, France
22
INSERM U917, CHU Pontchaillou, Rennes, France
23
Hopital Hotel Dieu, Laboratoire d'Hematologie, Nantes, France
24
25
Hematology Department, Necker University Hospital, AP-HP, Paris, France
14
3467 Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell
Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First
CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT
1
2*
3*
4
5*
Charles Craddock, MD, PhD , Jurjen Versluis , Myriam Labopin , Gerard Socie , Anne Huyn , Eric Deconinck,
6
7
8
9*
10
MD, PhD , Liisa Volin, MD, PhD , Noel Milpied, MD , Jean Henri Bourhis, MD, PhD , Alessandro Rambaldi, MD ,
11*
12
13*
14
Patrice Chevallier, MD, PhD , Didier Blaise, MD, PhD , Manz Markus , Edo Vellenga, MD, PhD , Marie
15*
16*
17
18*
Christiane Vekemans , Johan Maertens, MD, PhD , Jakob R. Passweg , Christoph Schmid , G J.
19
20
21
22
Ossenkoppele , Paresh Vyas, MD, PhD , Bob Löwenberg, MD, PhD , Mohamad Mohty, MD, PhD , Jan J.
23
24
Cornelissen, MD, PhD and Arnon Nagler, MD, MSc
1
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom
2
Erasmus University Medical Center, Rotterdam, Netherlands
3
Department of Hematology and Cell Therapy, Saint Antoine Hospital, Paris, France
4
Department of Hematology - BMT, Hopital St. Louis, Paris, France
5
Institut Universitaire Du Cancer, Toulouse, France
6
7
Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland
8
9
10
Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
11
12
13
University of Zurich, Zurich, Switzerland
14
Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center
Groningen, University Groningen, Groningen, Netherlands
15
University, Bruxelles, BEL
16
Department of Hematology, University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium
17
for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation,
(SAA WP-EBMT), Switzerland
18
2. Medizinische Klinik, Klinikum Augsburg, Augsburg, Germany
19
Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
20
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine and Department of
Haematology, University of Oxford, Oxford, United Kingdom
21
Editor-in-Chief, Blood, Erasmus University Medical Center, Rotterdam, Netherlands
22
23
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
24
Division of Hematology, Sheba Medical Center, Ramat Gan, Israel
238 A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and
over the Course of Treatment in Multiple Myeloma Patients
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Progression
1
2*
3*
4*
Nikhil C. Munshi, MD , Joaquin Martinez-Lopez , Victoria Carlton, Ph.D. , Stephanie Minvielle , Yu-Tzu Tai,
5
6
6*
7
8
PhD , Mariateresa Fulciniti, PhD , Mehmet K. Samur, PhD , Paul G. Richardson, MD , Michel Attal , Philippe
9*
4*
10
3
Moreau , Florence Magrangeas , Kenneth C. Anderson, MD , Malek Faham, MD, PhD and Hervé Avet11*
Loiseau
1
The Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA
2
Hospital-12-de-Octubre, Madrid, Spain
3
Adaptive Biotechnologies Corp, South San Francisco, CA
4
5
Harvard Medical School, the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston,
MA
6
MA
7
Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma
Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
8
9
10
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA
11
116 Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Biologic Insights from Genetics
1,2,3*
1,2,3*
4*
3*
5*
Francesco Maura
, Niccolo Bolli, MD
, Stephane Minvielle , Dominik Gloznik , Raphael Szalat , Anthony
3*
3*
6*
3*
3*
Fullam , Inigo Martincorena , Mehmet Kemal Samur, PhD , Patrick Tarpey , Helen Davies , Kevin J.
3*
3*
7*
3*
8*
9*
Dawson , Serena Nik-Zainal , Moritz Gerstung , Jorge Zamora , Yu-Tsu Tai , Cristiana Carniti , Florence
10*
10*
1,2
8*
3,11*
Magrangeas , Philippe Moreau , Paolo Corradini , Kenneth Anderson , David Wedge , Hervé Avet4*
3*
8,12
Loiseau , Peter Campbell and Nikhil Munshi
1
Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
3
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
4
5
Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA
6
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7
European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI), Hinxton, United
Kingdom
8
Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA
9
Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milano, Milan, Italy
10
Université de Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes, France
11
University of Oxford, Big Data Institute, Oxford, United Kingdom
12
Boston Veterans Administration Healthcare System, West Roxbury, MA
243 Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) ProgressionFree Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in
Relapsed/Refractory Multiple Myeloma (RRMM)
Type: Oral
Biomarkers
1*
2,3
4
5*
Alessandra Di Bacco, PhD , Nizar J. Bahlis, MD , Nikhil C Munshi, MD , Hervé Avet-Loiseau , Tamás Masszi,
6*
7*
8*
9*
10*
MD , Luísa Viterbo, MD , Ludek Pour, MD, PhD , Peter Ganly, BMBCh, PhD , Michele Cavo, MD , Christian
11
12
12
1
1*
Langer, MD , Shaji Kumar, MD , S. Vincent Rajkumar, MD , Deborah Berg, RN, MSN , Jianchang Lin, PhD ,
1*
1*
1*
1*
1*
1
Bin Li , Sunita Badola , Lei Shen , Jacob Zhang , Ling Wang, PhD , Dixie-Lee Esseltine, MD , Katarina
1
1*
13
14*
Luptakova , Helgi van de Velde, MD, PhD , Paul G. Richardson, MD and Philippe Moreau
1
Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,
Cambridge, MA
2
University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
3
University of Calgary, Calgary, AB, Canada
4
Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA
5
Hematology, IUC-Oncopole, Toulouse, France
6
Department of Haematology and Stem Cell Transplantation, St. Istvan and St. Laszlo Hospital of Budapest,
Budapest, Hungary
7
Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE), Porto,
Portugal
8
Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
9
Department of Haematology, Christchurch Hospital, Christchurch, New Zealand
10
Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy
11
University Hospital of Ulm, Ulm, Germany
12
Division of Hematology, Mayo Clinic, Rochester, MN
13
Dana-Farber Cancer Institute, Boston, MA
14
Hematology, University Hospital Hôtel Dieu, Nantes, France
3186 Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European
Leukemianet MDS (EUMDS) Registry
Myelodysplastic Syndromes—Clinical Studies
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
1,2*
3*
4*
4*
4*
Saskia Langemeijer, MD, PhD , Louise De Swart, MD , Ge Yu, MSc. , Alex Smith , Simon Crouch, PhD , Tom
5*
6
7
8
Johnston, PhD , Pierre Fenaux, MD, PhD , Argiris Symeonidis , Jaroslav Cermak , Eva Hellstrom-Lindberg, MD,
9
10
11*
12
13*
PhD , Guillermo Sanz, MD , Reinhard Stauder, MD , Luca Malcovati, MD , Ulrich Germing , Mette Skov
14*
15
16*
17*
Holm , Moshe Mittelman, MD , Krzysztof Madry, MD, PhD , Aurelia Tatic, MD , Antonio Almeida, MD,
18*
19
20
21*
22
PhD , Aleksandar Savic , Sophie Park, MD, PhD , Odile Beyne-Rauzy, MD , Raphaël Itzykson, MD, PhD ,
3*
23*
24
Corine van Marrewijk, Ph.D. , David Bowen, MD, PhD and Theo de Witte, MD, PhD
1
Radboud University medical Center, Nijmegen, Netherlands
Radboudumc, Nijmegen, Netherlands
3
Hematology, Radboudumc, Nijmegen, Netherlands
4
Epidemiology and Cancer Statistics Group, University of York, York, United Kingdom
5
University of York, York, United Kingdom
6
Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
7
Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece
8
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
9
Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Karolinska Institutet,
Stockholm, Sweden
10
Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
2
11
Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck,
Austria
12
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia,
Pavia, Italy
13
Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf,
Düsseldorf, Germany
14
Dept of Hematology, Aarhus University Hospital, Aarhus, Denmark
15
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
16
Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland
17
Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
18
Serviço de Hematologia, Lisbon, Portugal
19
Clinic of Hematology, Clinical Center of Vojvodina, Novi Sad, Serbia
20
Cochin Hospital, University Paris 5, Paris, France
21
Service d’hématologie, Centre Hospitalier Universitaire de Purpan, Toulouse, France
22
UMR7212/U944, Institut National de la Santé et de la Recherche Médicale, Saint-Louis Institute, University
Paris 7, Paris, France
23
St James's Institute of Oncology, Leeds, United Kingdom
24
Nijmegen Center for Molecular Life Sciences, Dep. of Tumor Immunology, Radboud University of Nijmegen
Medical Centre, Nijmegen, Netherlands
2776 Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated
in a Pediatric-Inspired Protocol – a Graall Study
Acute Lymphoblastic Leukemia: Clinical Studies
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II
1*
2*
3*
4*
Corentin Orvain , Marie Balsat, MD , Véronique Lhéritier , Emmanuelle Tavernier , Jean-Pierre Marolleau,
5*
6,7
8*
9*
MD, PhD , Thomas Pabst, MD, PhD , Patrice Chevallier, MD, PhD , Noémie De Gunzburg, MD , Victoria
10*
11*
12*
13*
6,14
Cacheux , Francoise Huguet, MD , Sylvain Chantepie, MD , Denis Caillot , Yves Chalandon, MD , Jamilé
15*
16*
17
17
Frayfer, MD , Caroline Bonmati, MD , Nicolas Boissel, MD, PhD , Hervé Dombret, MD, PhD , Norbert
18
1*
Ifrah and Mathilde Hunault-Berger, MD, PhD
1
Maladies du Sang, Angers University Hospital, Angers, France
2
Hématologie Clinique, Lyon-Sud Hospital, Pierre Benite, France
3
GRAALL Coordination, Lyon-Sud University Hospital, Pierre-Bénite, France
4
Hematology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France
5
Hématologie Clinique, Amiens University Hospital, Amiens, France
6
Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
7
Department of Hematology, Bern University Hospital, Bern, Switzerland
8
9
Hématologie Oncologie, Versailles Hospital, Versailles, France
10
11
Hématologie, Toulouse Cancer University Institute, Toulouse, France
12
Institut d'Hématologie, Caen University Hospital, Caen, France
13
14
Division of Hematology, Geneva University Hospitals, Geneva, Switzerland
15
Hématologie, Meaux Hospital, Meaux, France
16
Hématologie, Nancy University Hospital, Nancy, France
17
Hématologie Adulte, Saint-Louis Hospital, APHP, Paris, France
18
3271 Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and
Negatively Affect Prognosis
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
1*
1*
1*
Davine Hofste op Bruinink, MD, MSc , Hoogenboezem Remco, MSc , Mathijs A. Sanders, PhD , Christopher P
2*
2*
3*
1*
Wardell, PhD , Cody Ashby, PhD , Eric M.J. Bindels, PhD , Claudia Erpelinck-Verschueren, BSc , Paulette van
1*
1*
3*
4*
4*
Strien, BSc , Jasper Koenders, BSc , François G. Kavelaars, BSc , Jie He, PhD , Mark Bailey, MSc , Tariq I
4
5*
6*
7*
1
Mughal, MD, FRCP , Kristine Misund, PhD , Berna Beverloo, PhD , Bronno van der Holt, PhD , Ivo Touw, PhD ,
5
8*
9
2
Anders Waage, MD PhD , Hervé Avet-Loiseau , Graham H Jackson, MD, PhD , Gareth J Morgan, MD, PhD ,
2
1
Brian A Walker, PhD and Pieter Sonneveld, MD PhD
1
2
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
3
Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
4
Foundation Medicine, Inc., Cambridge, MA
5
KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway
6
Department of Clinical Genetics, Erasmus MC, Rotterdam, Netherlands
7
Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center, Rotterdam, Netherlands
8
IUC-Oncopole, Unité de Génomique du Myélome, Toulouse, France
9
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
1816 Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with
Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
1*
2*
3*
4*
Etienne Crickx, MD , Radjiv Goulabchand, MD , Claire Fieschi, MD, PhD , Lionel Galicier, MD , Paul Coppo,
5*
6*
7
8*
MD, PhD , Veronique Meignin, MD , Richard Delarue, MD , Olivier Casasnovas, MD , Veronique Leblond, MD,
9*
10*
11*
12*
13*
PhD , Guillaume Moulis, MD, PhD , Marc Michel, MD, PhD , Jehan Dupuis, MD , Fabien Le Bras, MD ,
14*
15
11*
Virginie Fataccioli, PhD , Corinne Haioun, MD, PhD , Bertrand Godeau, MD, PhD , Philippe Gaulard, MD,
16*
11*
PhD and Matthieu Mahevas, MD, PhD
1
Service de Médecine interne, Hôpital Henri Mondor, Créteil, France
2
Service de Médecine interne, Hôpital Saint Eloi, Montpellier, France
3
Service d'immunologie clinique, Hôpital Saint Louis, Paris, France
4
5
Hematology and Cellular Therapy, Saint Antoine Hospital, Paris, France
6
Pathology, APHP, Hopital Saint-Louis, Paris, France
7
Hematology Department, Necker University Hospital, AP-HP, Paris, France
8
Hematology Department, Hopital Le Bocage, CHU Dijon, Dijon, France
9
Department of Haematology, Hôpital de la Pitié-Salpétrière, Paris, France
10
11
12
Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor, CRETEIL, France
13
Service d'Hématologie Lymphoide, Hôpital Henri Mondor, Créteil, France
14
Inserm U955, APHP Hospital Henri Mondor, Creteil, France
15
Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
16
department of pathology, APHP, Groupe Hospitalier Mondor, CRETEIL, France
2088 Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a
Genomic Landscape with Diverse Evolutionary Pattern
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
1,2,3*
1,2,3*
4*
1*
5*
Niccolo Bolli, MD
, Francesco Maura
, Stephane Minvielle , Dominik Gloznik , Raphael Szalat , Anthony
1*
6*
1*
1*
1*
Fullam , Mehmet Kemal Samur, PhD , Patrick Tarpey , Helen Davies , Inigo Martincorena , Kevin J.
1*
1*
1*
7*
8*
9*
Dawson , Thomas Mitchell , Jorge Zamora , Cristiana Carniti , Yu-Tsu Tai , Florence Magrangeas , Philippe
9*
2,3*
8*
1,10*
4*
Moreau , Paolo Corradini , Kenneth Carl Anderson , David Wedge , Hervé Avet-Loiseau , Peter
1*
11,12
Campbell and Nikhil Munshi, MD
1
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
3
4
5
6
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7
Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milano, Milan, Italy
8
Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA
9
Université de Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes, France
10
11
Dana–Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA
12
Boston Veterans Administration Healthcare System, West Roxbury, MA
2
3458 Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in
Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular
Therapy Study
Session: 731. Clinical Autologous Transplantation: Results: Poster II
1*
2
3*
4
5
Remy Dulery, MD , Oumedaly Reman, MD , Ariane Boumemdil , Reda Bouabdallah, MD , Pauline Brice, MD ,
6*
7
8
9*
10
Thomas Gastinne, MD , Reza Tabrizi, MD , Philippe Quittet, MD , Anne Huynh, MD , Gilles Salles, MD, PhD ,
11*
12*
13
14*
Helene Monjanel , Aspasia Stamatoullas, MD , Jean-Henri Bourhis, MD, PhD , Caroline Bonmati, MD ,
15*
16*
17*
18
Sylvie Francois, MD , Stephanie Nguyen Quoc, MD PhD , Jacques Olivier Bay, MD , Jean-Yves Cahn, MD ,
19*
20*
1
Pascal Turlure, MD , Charles Dauriac, MD , Mohamad Mohty, MD, PhD , Regis Peffault De Latour, MD,
21*
22
PhD and Ibrahim Yakoub-Agha, MD, PhD
1
2
Hematology, CHU Caen, Caen, France
3
Biostatistics, EBMT LWP Office, Paris, France
4
Hematology, Institut Paoli-Calmettes, Marseille, France
5
Hematology, AP-HP Hopital Saint-Louis, Paris, France
6
Hematology, CHU Nantes, Nantes, France
7
8
Hematology, CHU Saint Eloi Montpellier, Montpellier, France
9
Institut Universitaire du cancer, Oncopole IUCT, Toulouse, France
10
Hematology, Hospices Civils de Lyon - Université de Lyon, Pierre-Bénite, France
11
Hematology, CHU Tours, Tours, France
12
Clinical Hematology, Centre Henri Becquerel, Rouen, France
13
Division of Hematology, Institut Gustave Roussy, Villejuif, France
14
15
Hematology, CHU Angers, Angers, France
16
Hematology Department, Pitie-Salpetriere Hospital, Paris, France
17
18
19
Hematology, CHU Limoges, Limoges, France
20
21
Hematology - Bone Marrow Transplantation, Saint Louis Hospital, Paris, France
22
Service des Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France
2861 Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia
(APL). a Report of 9 Cases
Prognosis: Poster II
1*
2*
3
4*
5*
Philippe Attias , Aline Renneville, MD , Xavier Thomas, MD, PhD , Cecile Bally , Sandrine Hayette , Hassan
6*
7*
8*
9*
Farhat, MD , Virginie Eclache, MD , Alice Marceau , Bruno Cassinat, PharmD, PhD , Jean Feuillard, MD- PhD,
10*
11*
12*
13*
14*
Pr , Christine Terré, PharmD, PhD , Eric Delabesse, PharmD, PhD , Sophie Park, MD, PhD , Julie Lejeune ,
15*
16
2
Sylvie Chevret, MD, PhD , Lionel Ades, MD, PhD , Claude Preudhomme, MD, PhD and Pierre Fenaux, MD,
17,18
PhD
1
Service d'Hématologie Senior, Hôpital Saint Louis, Paris, France
2
Hematology Laboratory, CHRU Lille, Lille, France
3
CHU, Lyon, France
4
5
Laboratory of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France
6
Hematology Department, CH Versailles, Versailles, France
7
Hematology Laboratory, CHU Avicenne, Bobigny, France
8
Haematology Laboratory, CHRU Lille, Lille, France
9
Service de Biologie Cellulaire, AP-HP, Hôpital Saint-Louis, Paris, France
10
Laboratoire d'hématologie, CHU Limoges, Limoges, France
11
Hematology Laboratory, Centre Hospitalier Andre Mignot, Versailles, France
12
13
CHU Grenoble Alpes, University Clinic of hematology, Grenoble, France
14
Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
15
Biostatistic, Saint-Louis Hospital, APHP, Paris, France
16
17
Groupe Francais des myélodysplasies (GFM), Paris, France
18
Saint-Louis Hospital, University Paris 7, Paris, France
788 Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained
Deep Molecular Response after TKI Re-Challenge
Chronic Myeloid Leukemia: Therapy
Type: Oral
Session: 632. Chronic Myeloid Leukemia: Therapy: TKI-Discontinuation
1*
2,3
4*
5*
Thomas Pagliardini , Franck E. Nicolini, MD, PhD , Stephane Giraudier, MD, PhD , Philippe Rousselot ,
2,6*
2,7*
2,8*
Gabriel Etienne, MD, PhD , Françoise Huguet, MD , Agnes Guerci-Bresler, MD, PhD , Bruno R. Varet, MD
9
10*
11*
12,13
PhD , Martine Escoffre, MD , Stephane Morisset, Stat , Francois-Xavier Mahon
and Laurence Legros,
2,14*
MD, PhD
1
CHU de Nice, Nice, France
2
Fi-LMC group, Pessac, France
3
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
4
Hôpital Henri-Mondor, Créteil, France
5
Centre Hospitalier, Versaille, FRA
6
7
France
8
Hematology Department, CHU Brabois, Nancy, France
9
Hematology Department, Hopital Necker-Enfants Malades / Paris Sorbonne Cité, Paris, France
10
CHU Rennes, Rennes, France
11
12
Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France
13
FILMC group, Bordeaux, France
14
Institut de Biologie Valrose, iBV, Nice, France
3705 A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib
in Clinical Trials
Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections
Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections:
Poster III
1
2
3
4
5
6
Laurie H Sehn, MD , Michael Hallek , Wojciech Jurczak , Jennifer R. Brown , Paul M. Barr , John Catalano ,
7
8
9
10*
11
Steven E. Coutre, MD , Richard R. Furman , Nicole Lamanna , Ysebaert Loïc , Andrew D. Zelenetz , Jeffrey P.
12
13*
14
14*
15
Sharman , Sven DeVos , Adeboye Henry Adewoye , Yeonhee Kim , Ian W. Flinn, MD, PhD and Gilles A.
16
Salles
1
Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
2
Dep. 1 of Internal Medicine, University of Cologne, Cologne, Germany
3
Department of Haematology, Jagiellonian University, Kraków, Poland
4
CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
5
Wilmot Cancer Institute, University of Rochester, Rochester, NY
6
Frankston Hospital and Monash University, Frankston, Australia
7
Stanford University School of Medicine, Stanford, CA
8
Weill Cornell Medical College, New York, NY
9
Leukemia Service, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, College
of Physicians and Surgeons, Columbia University Medical Center, New York, NY
10
Service d'Hématologie, Cancer Research Center of Toulouse, Toulouse, France
11
Memorial Sloan Kettering Cancer Center, New York, NY
12
Willamette Valley Cancer Institute and Research Center, US Oncology Research, Springfield, OR
13
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
14
Gilead Sciences, Inc., Foster City, CA
15
Sarah Cannon Research Institute, Nashville, TN
16
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hematologie, Universite Claude Bernard Lyon 1,
Lyon, France
347 Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count
AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Higher Risk MDS Clinical Studies
1,2*
3*
4*
5*
Marie Sebert, MD , Cecile Bally , Pierre Peterlin, MD , Odile Beyne-Rauzy, MD, PhD , Laurence Legros, MD,
6*
7*
8*
9
PhD , marie Pierre Gourin, MD, PhD , Laurence Sanhes, MD , Eric Wattel, MD PhD , Emmanuel Gyan, MD,
10
11*
12*
13*
14*
PhD , Sophie Park, MD, PhD , Aspasia Stamatoullas, MD , Anne Banos , Kamel Laribi, MD , Simone
15*
16*
17*
18*
1*
1*
Jueliger, PhD , Luke Bevan , Cendrine Chaffaut , Rosa Sapena , Benedicte Samey , Fatiha Chermat ,
19*
20
21
Sylvie Chevret , Lionel Ades, MD, PhD and Pierre Fenaux, MD, PhD
1
GFM, Hôpital Saint Louis, Paris, France
2
Service d’Hématologie Séniors, Hôpital St Louis, Université Paris 7, Paris, France
3
4
HOPITAL HOTEL DIEU ET HME, NANTES CEDEX 1, FRA
5
6
Hematology department, Hopital Archet 1, CHU Nice, Nice, France
7
CHU, Limoges, France
8
Department of Hematology, CH Perpignan, Perpignan, France
9
Lyon I University, Lyon, France
10
11
CHU Grenoble Alpes, University Clinic of hematology, Grenoble, France
12
Clinical Hematology, Centre Henri Becquerel, Rouen, France
13
Centre Hospitalier de la Cote basque, Bayonne, France
14
Centre Hospitalier, Le Mans, France
15
ASTEX pharmaceuticals, Cambridge, GBR
16
Astex Pharmaceutical, Cambridge, United Kingdom
17
Departement de biostatistiques, hôpital Saitn-Louis, Paris, France
18
Clinical Hematology, CHU Cochin, Paris, France
19
Statistics St-Louis Hospital, Paris 7, Paris, France
20
21
4060 Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of
Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results
from a First-in-Human Phase 1 Study
Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
1
2*
3*
4*
Tim Somervaille, MD PhD , Olga Salamero, MD , Pau Montesinos, MD, PhD , Christophe Willekens, MD , Jose
5*
6*
7
8*
Antonio Perez Simon, MD , Arnaud Pigneux, MD , Christian Recher, MD, PhD , Rakesh Popat , Cesar
9*
9*
10*
11
Molinero, MD, PhD , Christina Mascaro, PhD , Tamara Maes, PhD and Francesc Bosch, MD, PhD
1
The Christie NHS Foundation Trust, Manchester, United Kingdom
2
Hospital Universitari Vall d'Hebron, Barcelona, Spain
3
Hematology, Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain
4
Clinical Hematology, Gustave Roussy Cancer Center, Villejuif, France
5
Hospital Universitario Virgen del Rocío, Seville, Spain
6
Hôpitaux du Haut Lévéque CHU Bordeaux, Pessac, France
7
France
8
Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
9
Oryzon Genomics, Barcelona, Spain
10
Oryzon Genomics, Cornella De Llobregat, ESP
11
Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
2541 A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding
Situations in Immune Thrombocytopenia
1*
2*
3*
4*
Mathilde Roumier, MD , Louis Terriou, MD , Mohamed Hamidou, MD, PhD , Antoine Dossier, MD , Anne
5*
6*
7*
8*
Sophie Morin, MD , Virginie Zarrouk, MD , Mickael Ebbo, MD , Guillaume Moulis, MD, PhD , Lionel Galicier,
9*
10*
11*
12*
13*
MD , Sylvain Audia, MD, PhD , Laetitia Languille , Marie Goussef, MD , Solène Poutrel, MD , Marc
14*
14*
11*
Michel, MD, , Bertrand Godeau, MD, PhD and Matthieu Mahévas, MD, PhD
1
University, Creteil, France
2
Department of Internal Medecine, clinical immunology, Hôpital HURIEZ CHRU Lille, Lille, France
3
Department of Internal Medicine, Hôtel Dieu University Hospital, Nantes, France
4
Department of internal Medicine, Hôpital Bichat, Paris, France
5
Department of internal medicine, Hôpital Jean Verdier, Bondy, France
6
Deprtment of internal medicine, Hôpital Beaujon, Clichy, France
7
Department of internal medicine, Assistance publique Hôpitaux de Marseille, marseille, France
8
9
10
Department of internal medicine, Dijon university hospital, Dijon, FRA
11
Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri-Mondor, APHP, Créteil,
France
12
Deprtment of Internal Medicine, Centre hospitalier Bretagne Atlantique, Vannes, France
13
Department of Internal Medicine, Lyon university hospital, Lyon, France
14
356 A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and
Clinical Implications
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Insights from Molecular Alterations
and Alternate Splicing
1,2*
3*
4*
5,6*
Anil Aktas Samur, PhD , Mehmet Kemal Samur, PhD , Stephane Minvielle, PhD , Florence Magrangeas ,
7
8*
9
10
Mariateresa Fulciniti, PhD , Raphael Szalat , Paul G. Richardson, MD , Kenneth C. Anderson, MD , Michel
11
12*
3*
13*
7,14
Attal , Philippe Moreau , Giovanni Parmigiani, PhD , Hervé Avet-Loiseau and Nikhil C Munshi, MD
1
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA
2
Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA
3
4
Unité Mixte de Genomique du Cancer, Centre Hospitalier Universitaire de Nantes, Nantes, France
5
6
Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France
7
MA
8
9
Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma
Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
10
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA
11
12
13
Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale,
Toulouse, France
14
VA Boston Healthcare System, Boston, MA
236 The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed
By Whole-Genome Sequencing
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Progression
1*
2,3*
2,4*
5*
4*
Raphael Szalat , Niccolo Bolli, MD , Francesco Maura , Stephane Minvielle, PhD , Dominik Gloznik ,
6*
7*
4*
8*
4*
Florence Magrangeas , Philippe Moreau , Anthony Fullam , Mehmet K. Samur, PhD , Patrick Tarpey ,
9
4*
4*
4*
4*
Nicholas Anthony DaSilva, BS , Helen Davies , Inigo Martincorena , Kevin J. Dawson , Jose Tubio, PhD , Jorge
4*
10
10
4,11*
12*
Zamora , Yu-Tzu Tai, PhD , Kenneth C. Anderson , David Wedge , Hervé Avet-Loiseau , Peter J Campbell,
13*
10
MD, PhD and Nikhil C Munshi, MD
1
2
3
Wellcome Trust Sanger Institute, Cambridge, United Kingdom
4
5
6
7
8
MA
9
University of Rhode Island, Kingston, RI
10
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
11
12
13
Cancer genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
4643 Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell
Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia
Ttransplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective
Study on Behalf of the ALWP of the EBMT
Session: 731. Clinical Autologous Transplantation: Results: Poster III
1,2*
2*
2,3,4*
5
Giorgia Battipaglia , Annalisa Ruggeri , Myriam Labopin, MD
, Liisa Volin, MD, PhD , Didier Blaise, MD,
6
7*
8
9
PhD , Gerard Socié, MD, PhD , Noel Milpied, MD , Jan J. Cornelissen, MD, PhD , Ardeshir Ghavamzadeh,
10
11*
12*
13
14*
Professor , Anne Huynh, MD , Wu Depei , Ibrahim Yakoub-Agha, MD, PhD , Johan Maertens, MD, PhD ,
15*
2,16,17
3,18
Patrice Chevallier, MD, PhD , Mohamad Mohty, MD, PhD
and Arnon Nagler, MD, MSc
1
Hematology Department, Federico II University, Naples, Italy
2
3
Acute Leukemia Working Party of the EBMT, Paris, France
4
Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France, Paris, France
5
6
7
Hopital St. Louis, Dept.of Hematology – BMT, Paris, France
8
9
10
Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences,
Tehran, Iran
11
Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France
12
First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China
13
14
15
16
17
EBMT, Acute Leukemia Working Party, Paris, France
18
Division of Hematology, Sheba Medical Center, Ramat Gan, Israel
3245 Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with
Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
1
2*
2*
Mauricette Michallet, MD, PhD , Colette Chapuis-Cellier, Dr , Christine Lombard, Dr , Mohamad Sobh,
3*
4*
5*
6
7*
PharmD , Thomas Dejoie, PharmD , Helene Caillon, PharmD , Michel Attal , Philippe Moreau and Hervé
8*
Avet-Loiseau
1
2
Centre Hospitalier Lyon-Sud, Lyon, France
3
4
5
Biochemistry Laboratory, Nantes University Hospital, Nantes, France, Nantes, France
6
7
8
2892 Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia
1*
1*
2*
3
4*
Cecile Bally , Jacqueline Lehmann-Che , Bruno Cassinat, PharmD, PhD , Lionel Ades, MD, PhD , Eric Letouze ,
5,6*
7*
8
9*
Pierre Hirsch , Marie-Joelle Mozziconacci , Sophie Raynaud, MD , Eric Delabesse, PharmD, PhD , Madalina
10*
11*
12*
13*
Uzunov, MD , Mathilde Hunault, MD, PhD , Eric Lippert, PhD , Hélène Lapillonne, MD, PhD , Christophe
14
15*
16*
17*
Ferrand, PhD , Carine Gervais, MD , Nathalie Gachard, PhD, , Agnès Guerci, MD, PhD , Pierre Fenaux, MD,
18
19
PhD and Hugues de The, MD, PhD
1
2
Service de Biologie Cellulaire, AP-HP, Hôpital Saint-Louis, Paris, France
3
4
Integragen/GECO, Paris, France
5
INSERM U938, Paris, France
6
Service d'Hematologie et de Therapie cellulaire, Hopital St Antoine, Paris, France
7
Department of Cancer Biology, Institut Paoli Calmettes, Marseille, France
8
Laboratoire d'Oncohematolgie, Hopital Pasteur, Nice, France
9
10
Hematology Department, Pitie-Salpetriere Hospital, Paris, France
11
Hematology, Medical University Hospital, Angers, France
12
Laboratory of hematology, University Hospital Center of Bordeaux, Pessac, France
13
Hematology Laboratory, Trousseau Hospital, HUEP, APHP, Paris, France
14
EFS BFC, Inserm UMR1098, University hospital Besancon, University Franche Comte, Besancon, France
15
LRCHA, Strasbourg - Mulhouse, France
16
limoges, limoges, France
17
Hématologie Clinique, CHU Nancy-Brabois, Vandoeuvre, France
18
19
Univ. of Paris, Hospital St. Louis, Paris, France
4428 Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III
1*
2
3*
4*
5*
Helene Caillon, PharmD , Michel Attal , Hervé Avet-Loiseau , Cyrille Touzeau, MD , Philippe Moreau and
6*
Thomas Dejoie, PharmD
1
Biochemistry Laboratory, Nantes University Hospital, Nantes, France, Nantes, France
2
3
4
5
6
512 Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult
Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission:
An Analysis By the Acute Leukemia Working Party of the EBMT
Type: Oral
Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation
1*
2,3*
4
5*
6*
Sebastian Giebel , Myriam Labopin, MD , Michael Potter , Xavier Poiré, MD , Henrik Sengeloev, MD ,
7*
8*
9*
10
11*
Gerard Socié, MD, PhD , Anne Huynh, MD , Boris V Afanasyev, Professor , Urs Schanz, MD , Olle Ringden ,
12
13
14
15
Peter Kalhs, MD , Dietrich W. Beelen, Prof. Dr. med. , Antonio M. Campos, MD , Tamás Masszi, MD, PhD ,
2,16
2,17
Mohamad Mohty, MD, PhD and Arnon Nagler*, MD
1
Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer
Center and Institute of Oncology, Gliwice, Poland
2
Acute Leukemia Working Party of the EBMT, Paris, France
3
The Royal Marsden Center, London, United Kingdom
5
Section of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
6
Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
7
8
9
R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, Academician
I.P.Pavlov First St.Petersburg State Medical University, Saint-Petersburg, Russia
10
Division of Hematology, University Hospital Zurich, Zurich, Switzerland
11
Karolinska Institutet, Stockholm, Sweden
12
Medical University of Vienna, Vienna, AUT
13
Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen,
Germany
14
Serviço de Transplantação de Medula Óssea, Instituto Português de Oncologia, Porto, Portugal
15
St. István & St. Laszlo Hospital Semmelweis University St. Laszlo Campus, Budapest, Hungary
16
17
Chaim Sheba Medical Center, Tel-Hashomer, Israel
4
376 Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those
Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Clinical Insights from Multiple
Myeloma Biology and Biomarkers
1*
2
3*
4*
Thomas Dejoie, PharmD , Michel Attal , Philippe Moreau and Hervé Avet-Loiseau
1
2
3
Department of Hematology, Centre Hospitalier Universitaire-Nantes, Nantes, France
4
Introduction
3242 The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of
Chronic Lymphocytic Leukemia (CLL): An International Study
CLL: Therapy, excluding Transplantation
Session: 642. CLL: Therapy, excluding Transplantation: Poster II
1*
2*
3
4*
Philip A Thompson, MBBS , Vincent Levy, MD, PhD , Constantine S. Tam, MBBS , Chadi al Nawakil, MD ,
5*
6*
7*
8*
Francois Xavier Goudot, MD , Anne Quinquenel, MD , Loic Ysebaert, MD, PhD , Anne-Sophie Michallet, MD ,
9*
10
11*
1
Marie Sarah Dilhuydy, MD , Eric W Van Den Neste, MD, PhD , Jehan Dupuis, MD , Michael Keating, MBBS ,
12*
13
Christophe Meune, MD, PhD and Florence Cymbalista, MD, PhD
1
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2
Hôpital Avicenne, Bobigny, France
3
Peter MacCallum Cancer Centre & St. Vincent's Hospital, Melbourne, Australia
4
CRC, Hôpital Avicenne, Bobigny, France
5
Service de Cardiologie, Hôpital Avicenna, Bobigny, France
6
Hopital Robert Debre, Reims, France
7
Haematology dept, IUCT oncopole, Toulouse, France
8
Centre Léon Bérard, Lyon, France
9
Hôpital Haut-Lévêque, Pessac, France
10
Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
11
Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor, CRETEIL, France
12
Service de Cardiologie, Hôpital Avicenna, bobigny, France
13
Service d'hématologie biologique, Hôpital Avicenne, Bobigny, France
2899 Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise
Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients
from the Acute Leukemia Working Party of EBMT
1
2*
3*
4
5*
Jonathan Canaani, MD , Eric Beohou , Myriam Labopin , Gerard Socie, MD, PhD , Anne Huynh, MD , Liisa
6
7
8
9*
Volin, MD, PhD , Jan J. Cornelissen, MD, PhD , Noel Milpied, MD PhD , Tobias Gedde-Dahl , Eric Deconinck,
10
11*
12
13
14
MD, PhD , Jeremy Delage, MD , Didier Blaise, MD, PhD , Mohamad Mohty, MD, PhD and Arnon Nagler
1
Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Hopital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France
3
EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France
4
St-Louis Hospital, Paris, France
5
Institut Universitaire du cancer, Oncopole IUCT, Toulouse, France
6
7
8
France
9
Dept of Internal Medicine, Oslo University Hospital, Oslo, Norway
10
Department of Hematology, CHU Besancon, Besancon, France
11
Service d’Hematologie Clinique et Therapie Cellulaire, CHU de Bordeaux, Pessac, France
12
Programme de Transplantation et Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
13
Hôpital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France
14
Chaim Sheba Medical center and EBMT Acute Leukemia Working Party, Tel-Hashomer and Paris, Israel
2
2008 Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent
Patients with Low-Risk MDS and Iron Overload: The Rythmex Study
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I
1
2*
3
4*
5*
Christian Rose, MD, , Olivier Fitoussi, MD , Emmanuel Gyan, MD, PhD , Maya Hacini, MD , Shanti Amé, MD ,
6*
7*
8*
Bernadette Corront, MD , Odile Beyne-Rauzy, MD, PhD , Didier Innocent Adiko, MD , Elena-Anca Loppinet,
9*
10*
11
12*
MD , Nadia Ali-Ammar, MD , Eric Wattel, MD PhD , Francois Dreyfus, MD and Stéphane Cheze, MD,
13*
PhD
1
Hématologie clinique, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
2
Polyclinique Bordeaux Nord-Aquitaine, Bordeaux, France
3
4
service d'hematologie, Chambery, France
5
Hematology department, Hôpital Civil , CHU Strasbourg, Strasbourg, France
6
Centre Hospitalier Annecy-Gennevois,, Annecy, France
7
8
Hôpital Robert Boulin, Libourne, Libourne, FRA
9
service d'hématologie, CH Metz, Metz, France
10
service d'hématologie, CH Troyes, Troyes, France
11
Lyon I University, Lyon, France
12
CHU Cochin, Hematology, Paris, France
13
Institut d’Hématologie de Basse-Normandie, CHU Caen Hôpital Côte de Nacre, Caen, France
4462 Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific
Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target
Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III
1*
2,3*
4*
1*
5,6*
Xiu Ly Song , Raphaël Szalat, MD , Alexis Talbot, MD , HaiVu Nguyen, pHD , Mehmet K. Samur, PhD ,
7,8*
9
10*
11*
David Mosen-Ansorena, PhD , Nikhil C. Munshi, MD , Stephane Minvielle, PhD , Hervé Avet-Loiseau ,
12*
1,13
1,14*
Wendy Cuccuini, MD, PhD , Jean-Paul Fermand, MD , Bertrand Arnulf, MD, phD
and Jean-Christophe
15*
Bories
1
INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris,
France
2
Medical Oncology, Harvard Medical School, Boston, MA
3
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4
INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité,, Paris,
France
5
MA
6
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical
Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7
Harvard School of Public Health, Boston, MA
8
9
10
11
12
Haematology Laboratory, Saint-Louis Hospital, APHP, Paris, France
13
Immuno-Hematology Unit, Saint-Louis Hospital, Paris, France
14
France;, Paris, France
15
FRA
4563 Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid
Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete
Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III
1,2
3*
4*
5
6
Yishai Ofran, MD , Eric Beohou , Myriam Labopin , Didier Blaise, MD, PhD , Jan J. Cornelissen, MD, PhD ,
7
8*
9*
10*
Marco R De Groot, MD, PhD , Gerard Socié, MD, PhD , Anne Huynh, MD , Johan Maertens, MD, PhD ,
11
12
3,13
Frederic Baron, MD, PhD , Mohamad Mohty, MD, PhD and Arnon Nagler
1
Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel
2
Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
3
Hopital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France
4
EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France
5
6
7
Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen,
Netherlands
8
9
10
11
Hematology & GIGA Research, University of Liege, Liege, Belgium
12
13
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, and
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
2070 Evaluation of the Concordance of Two Free Light Chains Assays to Identify High Risk Smoldering
Myeloma Patients.
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
1*
1*
2*
3*
2*
3
Caroline Moreau , Emmanuel Rouger , Basile Henriot , Martine Escoffre , Martine Sebillot , Thierry Lamy ,
4*
5*
2*
Stéphane Minvielle , Hervé Avet-Loiseau and Olivier Decaux, MD, PhD
1
Biochemistry, University Hospital CHU Rennes, Rennes, France
2
3
Hematology, University Hospital CHU Rennes, Rennes, France
4
UMR 892 Inserm - 6299 CNRS, Nantes, France
5
195 RNA-Seq De Novo Assembly of Clonal Immunoglobulin Rearrangements Identifies Interesting Biology
and Uncovers Prognostic Features in Multiple Myeloma
Type: Oral
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Prognostic Factors
1,2*
3*
4,5*
David Mosen-Ansorena, PhD , Rachael Bashford-Rogers, PhD , Niccolo Bolli, MD , Stephane Minvielle,
6*
6*
7
8*
2*
PhD , Florence Magrangeas , Kenneth C Anderson, MD , Hervé Avet-Loiseau , Giovanni Parmigiani, PhD and
9,10
Nikhil C Munshi, MD
1
Harvard School of Public Health, Boston, MA
2
3
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
4
5
Wellcome Trust Sanger Institute, Cambridge, United Kingdom
6
7
Dana-Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA
8
9
VA Boston Healthcare System, Boston, MA
10
MA

Télécharger la liste des 67 posters

Transcription

Documents pareils

Voir la fiche

Greffe du rein : l`expertise du CHU de Toulouse reconnue dans un

Transcription textuelle de la carte de vœux 2017 du CHU de Toulouse

PROFIDYS - Dysplasie fibreuse des os

Programme JE Musique en mouvemebre 8 décembre - cral

Université des Sciences Sociales Année universitaire 2000-2001

Symposium L`actualité de la recherche en droit franco

Erasmus Student Placement